Functional polymorphism of a human Fc receptor for murine IgG2b by Holtrop, S.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/145719
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Functional 
polymorphism 
of a human 
Fc receptor for 
murine lgG2b 
Sjoukje Holtrop 

Functional polymorphism of a human Fc receptor 
for murine IgG2b 
Sjoukje Holtrop 

Functional polymorphism of a human Fc receptor 
for murine IgG2b 
een wetenschappelijke proeve 
op het gebied van de Medische Wetenschappen 
PROEFSCHRIFT 
ter verkrijging van de graad van doctor 
aan de Katholieke Universiteit Nijmegen, 
volgens besluit van het College van Decanen 
in het openbaar te verdedigen 
op dinsdag 11 januari 1994, 
des namiddags te 3.30 uur precies 
door 
Sjoukje Holtrop 
geboren op 8 juli 1957 
te Sneek 
Promotor: prof. dr. R.A.P. Koene 
Co-promotor: dr. W.J.M. Tax 
The research presented in this thesis was performed in the Department of Medicine, Division 
of Nephrology, University Hospital St. Radboud, Nijmegen, The Netherlands. 
Druk: DRUKKERU BENDA BV, Nijmegen. 
°1993. All rights reserved. 
No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any 
form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written 
permission from the copyright owners. 
CIP-GEGEVENS KONINKLIJKE BIBLIOTHEEK, DEN HAAG 
Holtrop, Sjoukje 
Functional polymorphism of a human Fe receptor for murine IgG2b / 
Sjoukje Holtrop. - [S.l. : s.n.]. - 111. 
Proefschrift Nijmegen. - Met lit. opg. - Met samenvatting in het Nederlands. 
ISBN 90-9006736-1 
Trefw.: Fe receptoren / polymorfisme / immuunsuppressie. 
Ta oantinken oan Heit en Mem 
Aan Joop 
Oan Jan 
ABBREVIATIONS 
aa 
ADCC 
BSA 
CD 
c.p.m. 
EA-mlgG 
EA-mIgG2b 
EBV 
ELISA 
FACS 
Fc?R 
FceR 
FcR 
FCS 
FITC 
g 
h 
HLA 
HR 
hr 
HRBC 
Ig 
IgE 
IgG 
IFN7 
IL 
kDa 
LR 
m 
mAb 
МНС 
mIgG2b 
mlgGl 
min. 
η 
PBMC 
PBS 
SD 
SDS-PAGE 
SI 
TcR 
amino acid residues 
antibody-dependent cell-mediated cytotoxicity 
bovine serum albumin 
cluster of differentiation 
counts per minute 
erythrocytes sensitized with murine IgG 
erythrocytes sensitized with murine IgG2b mAb 
Epstein-Ватт vims 
enzyme-linked immunosorbent assay 
fluorescence activated cell sorter 
receptor for Fc moiety of IgG 
receptor for Fc moiety of IgE 
receptor for Fc moiety of immunoglobulin 
foetal calf serum 
fluorescein isothiocyanate 
unit of gravity 
human 
human histocompatibility leucocyte antigens 
high-responder 
hour 
human red blood cells 
immunoglobulin 
immunoglobulin E 
immunoglobulin G 
interferon-γ 
interleukin 
kilodalton 
low-responder 
murine 
monoclonal antibody 
major histocompatibility complex 
murine immunoglobulin G, isotype 2b 
murine immunoglobulin G, isotype 1 
minutes 
number in study or group 
peripheral blood mononuclear cells 
phosphate-buffered saline 
standard deviation 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
stimulation index 
Τ cell receptor for antigen 
VI 
Contents 
Chapter 1 General introduction 1 
Chapter 2 Removal of monocytes from cell suspensions with anti-
CD14 antibody and carbonyl-iron, using Fc7R-dependent 
accessory function as a sensitive measure of monocyte 
presence. 
J. Immunol. Methods 156: 217 - 222 (1992) 41 
Chapter 3 A polymorphic Fc receptor for mouse IgG2b on human 
В cells and monocytes. 
Immunology 74: 613 - 620 (1991) 53 
Chapter 4 The human Fc receptor for mouse IgG2b on monocytes 
and EBV-B cells is functionally inhibited by anti-HLA 
class II antibodies. 
Scand. J. Immunol. 37: 195 - 201 (1993) 75 
Chapter 5 Proteolysis increases the Fc-mediated binding of murine 
IgG2b to human EBV-transformed В cells, but decreases 
the expression of Fc7RII and FceRII. 
Scand. J. Immunol. 38: 259 - 266 (1993) 93 
Chapter 6 Clinical implications of the polymorphic interaction of 
murine IgG2b and IgGl with human Fc receptors. 
Transplant Immunology 1: 252 - 254 (1993) I l l 
Chapter 7 Summary 121 
Samenvatting 127 
Dankwoord 133 
Curriculum vitae 135 
VII 

Chapter 1 
General introduction 

GENERAL INTRODUCTION 
The production of specific immunoglobulin (Ig) molecules (antibodies) is a 
central process in the immune response. Ig molecules exist in two different 
forms: as cell surface bound receptors that serve as antigen receptors present 
on В lymphocytes, or as proteins that are secreted by plasma cells to capture 
soluble or cell-bound antigens. Five classes of Ig molecules are characterized 
by specific antigenic determinants in their heavy chains: IgG (7), IgM (μ), IgE 
(e), IgA (a) and IgD (δ) (180). IgG molecules which are the prominent glyco­
proteins in serum are further divided in distinct subclasses; in man: human 
(h)IgGl, hIgG2, hIgG3 and hIgG4; in the mouse (m): mlgGl, mIgG2a, 
mIgG2b and mIgG3. 
In addition to their specific binding to cell-bound or soluble antigen, the non­
specific binding of IgG to human monocytes (63), human neutrophils (103) and 
to murine macrophages (81) was already described more than twenty-five years 
ago. Later, a similar binding to mouse В lymphocytes was observed by 
Paraskevas (112). From this latter study it appeared that the cells had affinity 
for the Fc portion of the immunoglobulins. On this basis the term "Fc receptor" 
was proposed for these binding sites (111). The Fc receptors (FcR) present on 
several types of cells are able to bind antigen-antibody complexes and to 
remove them from the body fluids. In this way, Fc receptors function as linkage 
molecules between the humoral and the cellular immune response. 
In these early years binding of IgG or IgM by FcR was also observed on 
murine Τ cells and on human В cells. Binding of IgE was demonstrated on В 
cell suspensions contaminated with basophils; IgA or IgD binding was not 
reported (39). In the late 1970s, Fc receptors expressed on murine В cells were 
already found to be structurally different from the surface (s) Ig molecules, 
complement receptors, or MHC class II (H-2 Ir-gene associated) molecules; 
differences were found in molecular weight of the receptor molecules, in studies 
on inhibition of binding or (co-)capping of receptor molecules, and sensitivity 
to proteolytic enzymes like trypsin (39). 
Due to several newly developed techniques that became available in 
biochemistry and immunology during the 1970s, research has extensively 
increased. The EA-rosetting technique which was already described in the late 
3 
Chapter 1 
1960s (90) appeared to be necessary in defining the presence of Fc-binding 
molecules. The technique is based on indicator erythrocytes (RBC) that are 
sensitized with Ig molecules of an appropriate isotype; subsequently, the 
sensitized RBC are incubated with different cell types whereafter the formation 
of rosettes proves the presence of Fc receptors on the type of cells under study 
(Figure 1). Later, this technique has been refined and extended (72) by using 
appropriate and well-defined (monoclonal) antibodies in combination with 
properly isolated and purified cells and cell suspensions. 
FcR mlgCHb 
<ί «ее К — _<T RBC b — 
>- mlg02b anti-glycophorin A mAb 
Figure 1. 
EA-mIgG2b resetting. 
Human red blood cells (RBC) are sensitized with anti-glycophorìn A mAb and are incubated 
with cells that express an appropriate FcR that is cross-reactive with murine immunoglobulin. 
In the present example, the RBC were sensitized with mIgG2b anti-glycophorin A mAb in 
order to study the FcR for mIgG2b. The percentage of EA-rosettes (cells which have bound 
at least three RBC) can be scored microscopically. 
The further characterization of FcR for IgG (FC7R) and FcR for IgE (FceR) 
expressed on blood cell subsets and cell lines of human, murine or rat origin 
received much attention whereas FcR for IgM, Ig A or IgD were hardly studied 
(32,95). In the latest decade, several isoforms of FCYR as well as of FceR, 
expressed on different hematopoietic cell types, have been well-characterized 
(also at the molecular level), and studies have been initiated with respect to 
their function. 
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CLASSIFICATION OF Fe RECEPTORS 
Until now, three groups of Fc receptors have been defined (76,96). 
Nomenclature as proposed (128) will be used here. The first group consists of 
Fc receptors belonging to the immunoglobulin gene superfamily (66,187). This 
group includes Fc receptors that bind IgG with high-affinity (Fc7RI) or low-
affinity Fc?R (FCYRII and FCYRIII), the high-affinity FcR for IgE (FceRI) 
(13,104), the MHC class I-like FC7R which functions as an IgG transport 
molecule (12,145), and the polymeric IgA and IgM (poly-Ig) receptors (12,53). 
The second group of Fc receptors belongs to the calcium-dependent (C-type) 
animal lectin family (185), e.g. the low-affinity FcR for IgE (FceRII; CD23). 
The third group of Fc receptors includes the FcR for IgA, IgM or IgD (22). 
The investigations presented in this thesis deal with the interaction of human 
FcR with murine IgG2b m Ab. These studies were performed with human 
monocytes and В cells. Since only Fc-yRI, FC7RII and FceRII are present on 
resting monocytes and/or В cells (as illustrated in Figure 2) these Fc receptors 
will be discussed primarily. 
FcR mlgG2b FcR mlgG2b 
Figure 2. A В 
Expression of Fc receptors on human monocytes (A) and В cells (B). 
Constitutive expression of Fc-yRI, FcyRII and the FcR for mIgG2b is found on monocytes 
whereas FceRII can be induced by IL4. Fc?RIII is expressed on monocytes only after in vitro 
culture. On (EBV-transformed) В cells FcyRII, FCÍRII and the FcR for mIgG2b are 
consütuúvely expressed. 
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HUMAN Fe RECEPTORS FOR IgG; hFc?R 
History: In 1968, IgG binding to FcR-like structures on human cells was 
already described (63). In 1980, in humans the high-affinity FcR for IgG was 
first identified on myeloid cell lines U937 (4) and HL60 (34). On human 
myeloid cells (cell line U937) this FcR for IgG was shown to be trypsin-
rçsistant (8), in contrast to its murine counterpart (163,165). Monomeric hlgGl 
and hIgG3 were reported to bind to human mononuclear phagocytes (3,85). 
Almost simultaneously, different Fc receptors were isolated from human В and 
non-B cells (30,83). Further studies revealed the existence of two Fc>R 
molecules with either high or low avidity for IgG on human macrophages (86) 
and on human myeloid cell line U937 (71). In 1986, on human monocytes these 
two FcR molecules were isolated and characterized by using affinity 
chromatography, immunoprecipitation with mAb (91), and differential ligand 
binding affinity (190). The presence of two FcR on human monocytes was also 
confirmed by anti-CD3 mAb induced Τ cell proliferation (29), EA-rosetting 
assays (172), modulation (173) and antibody-dependent cell mediated 
cytotoxicity (ADCC) (168). 
One FC7R has high-affinity binding for human IgG, and can even bind 
monomeric hlgGl and hIgG3. This receptor, a 72 kDa glycoprotein, is called 
I1FC7RI. A second class of FcyR, hFc7RII, has a low-affinity binding, and can 
bind complexed hlgGl and hIgG3. Its molecular weight is 40 kD. This Fc 
receptor for IgG on human monocytes and myeloid cell lines was proposed to 
be homologous to the low-affinity FcR for IgG on murine macrophages (166) 
identified by mAb 2.4G2 (126,164). On human monocytes, both hFc7RI and 
hFcvRII were found to be resistant to proteolytic enzymes. Remarkably, 
proteolysis strongly enhances the binding affinity of the human low-affinity 
I1FC7R on monocytes (155,174). The hFc7RII was also detected on human 
platelets (132), neutrophils and eosinophils (93). Proteolytic treatment of human 
neutrophils demonstrated that the hFc7RII was resistant to leucocyte elastase 
(161). A third class of hFc7R, later defined as I1FC7RIII (another low-affinity 
receptor) is present on human neutrophils, macrophages, natural killer (NK) 
cells and cultured monocytes (128,167). Immunoprecipitation of hFc7RIII 
reveals a broad band (50 - 80 kD), due to heterogeneity of glycosylation. On 
human neutrophils, the hFc7RIII is abundantly glycosylated and glycosylation 
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is important for ligand binding (74). Expression of hFc7RIII on neutrophils is 
sensitive to treatment with pronase or leucocyte elastase (50,161). 
Cross-reactivity: All three hFc7R can be cross-reactive to some extent with 
murine immunoglobulins of different isotypes. hFc7RI can bind mIgG2a and 
mIgG3 antibodies (even in monomenc form), whereas hFc-yRII can interact 
with mlgGl sensitized cells (91,94) and perhaps with aggregated mIgG2b (71). 
hFcyRIII can also bind mlgG, primarily mIgG3, with low-affinity. 
General functions: The general characteristics of the three different FCYR 
classes are presented in Tables 2, 3 and 4 (see below). Macrophages 
constitutively express all three Fc7R receptor classes (75,128,167). On most 
cell types, expression of FCYR is regulated by cytokines. Cytokines can induce 
additive or antagonistic effects on the expression of FC7R (15). The three FC7R 
classes are involved in the mediation of calcium fluxes, phagocytosis, 
generation of superoxide, release of inflammatory mediators, and ADCC (169). 
Binding epitopes in the lower hinge region (CH2 domain) of IgG are essential 
in FcYR-mediated activation (22). The molecular structure of the hFc7R 
molecules was first identified during the late 1980s (2,137,150) and has been 
extensively reviewed in recent years (128,167,169). 
The "Kurlander phenomenon": Several mAb against FcR (Table 1) have been 
described that are very useful in studying Fc receptors. Some of these mAb 
bind to the ligand binding site of the FcR and in this way block FcR 
functioning. Antibodies, however, can also block FcR by a different 
mechanism: the "Kurlander phenomenon". As was first described by Kurlander 
(84), the Fc moiety of an antibody that is specific for a cell surface antigen may 
also bind to an FcR expressed on the same cell, resulting in a tripartite binding 
of one IgG molecule to a single cell. Use of F(ab')2 fragments of the IgG 
molecule can discriminate between the "Kurlander-type" of inhibition, or Fab-
mediated inhibition. 
In contrast to inhibition of FcR functions mediated by blockade of the ligand 
binding site via the Fab part of anti-FcvR mAb or via the "Kurlander 
phenomenon" via the Fc part, stimulatory effects on FcR functioning have been 
reported as well. A special case of the "Kurlander phenomenon" arises when 
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Table 1. Characteristics of some anti-human Fc receptor mAb 
Antigen 
FC7RI 
(CD64) 
FC7RII 
(CD32) 
FC7RIII 
(CD 16) 
FceRII 
(CD23) 
mAb 
197 
10.1 
22 
32 
44 
62 
CIKM5 
IV.3 
KB61 
41H.16' 
2E1 
KuFc79 
CIKM3 
3G8 
B73.1 
CLBgran 1 
CLBgran llb 
GRM lb 
Leu 11a 
Tul 
MHM6 
25 
Isotype 
mIgG2a 
mlgGl 
mlgGl 
mlgGl 
mlgGl 
mlgGl 
mlgGl 
mIgG2b 
mlgGl 
mIgG2a 
mIgG2a 
mIgG2b 
mlgM 
mlgGl 
mlgGl 
mIgG2a 
mIgG2a 
mIgG2a 
mlgGl 
mlgGl 
mlgGl 
mlgGl 
Blockade of 
ligand binding 
site 
yes (via Fc) 
yes (via Fab) 
no 
no 
no 
no 
yes (via Fc) 
yes (via Fab) 
no 
no 
no 
yes 
no 
yes (via Fab) 
no 
yes 
no 
no 
no 
no 
yes 
yes 
References 
(60) 
(40) 
(60) 
(5) 
(107) 
(5) 
(159) 
(91,132) 
(125) 
(11,56) 
(47) 
(177,188) 
(159) 
(48,51,120,121) 
(48,117,121) 
(48,118) 
(48,65,118,159,162) 
(48,65,139,162) 
(121,123) 
(18) 
(18,133) 
(18) 
a) This antibody recognizes the polymorphism in hFc7RIIa. 
b) These antibodies recognize the allelic forms hFc7RIIIb-NAl (CLBgran 11) and 
hFc7RIIIb-NA2 (GRM 1). 
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a mAb directed against an FcR also binds by its Fc moiety. This antibody can 
then cross-link two FcR molecules without the use of second antibodies as 
bridging molecules, and activate the FcR-positive cells. 
Until now, this mechanism was reported for two anti-Fc7R mAb, mAb 197 
(anti-hFcYRI; mIgG2a) and CIKM5 (anti-hFc7RII; mlgGl) (98,99,171). 
Triggering via IIFCYRI by mAb 197 was measured in superoxide generation 
(122) and intracellular calcium responses (80,99,171); stimulation of hFcvRII 
by mAb CIKM5 was evident from intracellular calcium responses (97,98,171) 
and ADCC (80). 
Functional polymorphism mediated by FcyR: The presence of Fc receptors in 
a mononuclear cell suspension has been analyzed in a Τ cell proliferation assay 
by using anti-CD3 mAb (156). The anti-CD3 mAb induced mitogenic response 
of Τ cells is supported by FcR-positive accessory cells and only occurs when 
the Fc part of the anti-CD3 mAb is able to interact with appropriate Fc 
receptors on the accessory cells (Figure 3). 
anti-CD3/TCR 
Τ cell proliferation assay. 
A mitogenic response of Τ cells induced by anti-CD3/T cell receptor (TcR) mAb requires 
the interaction of the Fc moiety of the antibody with an appropriate FcR on FcR-positive 
accessory cells. In this model Τ cell proliferation (measured by pHJ-thymidine 
incorporation), therefore, provides an indirect measure of FcR function. 
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Table 2. General characteristics of human FcyRI 
Cluster Differentiation CD64 
Protein (kDa) 
Cellular distribution 
FcvRIa: 72 
monocytes/ macrophages; 
neutrophils (after IFN7); 
neutrophils (after G-CSF) 
Polymorphism Absence of receptor described in 
one family 
Ligand binding and rankorder hlgG: 3 > 1 > 4 > > > 2 ; 
mlgG: 2 a = 3 > > > l = 2 b ; 
rabbit IgG 
Affinity for hlgG (Ka) 10' - 10' м-1 
Protein structure 
Signal transducing proteins 
single chain 
FcyRIa: 3 Ig-like domains 
Fc7RIb2: 2 Ig-like domains 
associated 77-homodimer ? 
Gene localization (chromosome) 1 q21.1 
Number of genes; isoforms 
(TM: transmembrane receptor) 
3 genes; 4 isoforms 
Fc-yRIa ; TM 
Fc7RIb2 ; TM 
Fc7RIbl ; soluble 
FC7RIC ; soluble 
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Induction of a Τ cell proliferative (mitogenic) response by mIgG2a (or mIgG3) 
anti-CD3 mAb mediated via I1FC7RI is measured in peripheral blood 
mononuclear cells (PBMC) from all individuals except four individuals from 
one Belgian family (24,169), whereas a proliferative response to mlgGl anti-
CD3 mAb via I1FC7RII is measured in about 70 - 80% (High-Responders: 
mlgGl-HR) of the Caucasian, Negro and American Indian individuals tested 
(1,156,175); by contrast, in a population of Japanese individuals only 15% has 
been shown to be high-responder to mlgGl anti-CD3 mAb (1). Τ cell activation 
mediated by mIgG2b anti-CD3 mAb occurs in about 10% of the Caucasian 
individuals (146,157,175). 
Furthermore, a polymorphism in the neutrophil specific antigen system, NA1 
and NA2 located on the neutrophilic hFc7RIII molecule is demonstrated by 
serology (87,159). The transmembrane hFc7RIII present on cultured 
monocytes/macrophages and NK cells is not polymorphic (41). 
The human high-affinity Fc receptor for IgG; hFcvRI; CD64 
General expression ofhFcyRI: The human high-affinity receptor for IgG (Table 
2) is constitutively expressed on monocytes, macrophages and myeloid cell lines 
like U937, HL60 and THP-1 (49). Expression of hFc7RI can be upregulated 
by IFN7 on cultured monocytes and phagocytes of alveolar (6) or placental 
(142) origin and induced on neutrophils in vitro (119,144) and in vivo (59). 
Increased I1FC7RI expression on blood monocytes is induced by IFN7 (55,70), 
glucocorticoids (110) or a combination of these agents (55), and by ILIO (158). 
Additionally, IFN7 affects the cytolytic activity of cultured monocytes: 
treatment with IFN7 (9 days) perform hFc7RI-mediated ADCC whereas in the 
absence of additional stimuli long-term cultured monocytes mediate hFc7RI-
induced phagocytosis. Monocytes cultured for a short period (40 hr) in the 
presence of IFN7 are able to mediate both functions (176). 
By using anti-Fc7RI mAb (Table 1) at least three epitopes on hFc7RI have been 
determined: the ligand binding site which is blocked by mAb 10.1; a second 
epitope detected by mAb 22 and 44; and a third epitope recognized by mAb 32 
and 62 (46). On monocytes and U937 cells, I1FC7RI has an additional binding 
site for C-reactive protein, an acute-phase protein (35). 
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Molecular structure ofhFcyRI: The hFc7RI molecule possesses an extracellular 
region with three Ig-like domains and is encoded by the hFc7RIA gene (the 
hFc7RIa transcript) (2,170). Recently, an isoform encoded by the hFc7RIB 
gene, the hFc>RIb2 transcript, was isolated which has lost the coding sequence 
for the third domain that mediates the high-affinity binding of the receptor. The 
cytoplasmic tail is identical to that found in the hFc7RIa encoded molecules 
(45,124). Furthermore, two soluble products encoded by hFc7RIbl and 
hFc7RIc transcripts have been isolated (45). 
Signal transduction via hFcyRI: Stimulated expression and signal transduction 
via I1FC7RI is induced by IFN7 and occurs on the transcriptional level. 
Recently, a DNA binding factor has been described (189) which recognizes the 
conserved motif of an IFN7-response region on the I1FC7RI gene (16,115). 
Single cell analysis of transfected cells with hFc7RIa isoform (wild-type) or 
deletion mutants expressing a transmembrane protein without a cytoplasmic tail 
(tail-minus) demonstrated that binding of IgG can be mediated by both receptor 
molecules whereas triggering of intracellular calcium and, subsequently, 
induction of phagocytosis can only be mediated by the hFc7RIa wild-type 
transfected cells (69). Cross-linking of hFc7RI molecules was recently reported 
to induce phosphorylation of phospholipase C-7I (PLC-7I) via cytoplasmic 
tyrosine kinases functionally coupled to the Fc receptor (89). 
Furthermore, in cultured macrophages hFcR-mediated (and also complement 
receptor CRI- and CR3-mediated) phagocytosis, triggered by protein kinase C, 
require intact actin filament assembly of the cellular cytoskeleton. With respect 
to hFc7RI (not I1FC7RII or hFc7RIII) a direct intracellular association with an 
actin-binding protein has been reported. The actin-binding protein, a homodimer 
of 280 kDa is a cross-linking protein of actin filaments and is involved in 
stabilizing the cellular membrane. Extracellular binding of IgG molecules to 
I1FC7RI disrupts (in a dose-dependent way) the intracellular complex of actin 
binding protein-hFc7RI immediately (within one minute) (109). Similar results 
have been found with respect to the murine FC7RII/32 expressed on 
macrophages: binding of immune complexes reduces the association of 
mFc7RII/32 and cytoskeletal proteins and results in impaired phagocytosis of 
these cells (152). In this context it is interesting to speculate on the 
physiological role of hFc7RI in vivo. Due to high concentrations (± IO"5 M) 
of hlgG in plasma and the high-affinity binding of the receptor, I1FC7RI is likely 
to be saturated with (monomeric) hlgG and, thus, intracellular^ dissociated 
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from the actin binding protein. As a result, hFc7RI-mediated phagocytosis 
might also be reduced in vivo. 
The human low-affinity Fc receptor for IgG; hFc-yRII; CD32 
General expression of hFcyRII: The Ì1FC7RII (Table 3) has a broad cellular 
distribution and is expressed on monocytes and macrophages, neutrophils, В 
cells, eosinophils, and platelets (167). Furthermore, the human low-affinity 
hFc7RII is also present on epidermal Langerhans cells (140,141), human 
basophils (10), Schwann cells and perineurial cells (178), and on several cell 
lines such as the proerythro-myeloid cell line K562 (25,67) and the myeloid cell 
lines U937 and HL60 (101). In vitro, release of hFciRII from blood 
lymphocytes (102) and activated В cells (135,136) has been found whereas, in 
vivo, release of soluble hFc7RII in serum has been reported in patients on 
hemodialysis and after renal transplantation (68). 
General fitnctions of hFcyRII: Freshly isolated hFc7RII-positive neutrophils and 
eosinophils have been reported to be unresponsive in initiating I1FC7RII-
mediated ADCC (57) or superoxide production (131). By contrast, freshly 
isolated monocytes are able to mediate ADCC of sensitized human erythrocytes 
(168). Cross-linking of proteins encoded by hFeyRIIa transcripts or by 
I1FC7RIIC (that encodes a cytoplasmic region identical to hFc7RIIa but different 
from hFc7RIIbl or hFc7RIIb2) results in an increased intracellular calcium 
response (79,131). Furthermore, treatment of monocytes with IFN7 and/or the 
synthetic glucocorticoid dexamethasone does not cause modulation of hFc7RII 
mRNA or protein whereas on U937 cells hFc7RII is upregulated by IFN7 (31). 
In addition, cytokines like IL4 might also be involved in differential functioning 
of monocyte I1FC7R, e.g. IL4 downregulates hFc7RI-mediated phagocytosis and 
also diminishes hFc7RII-mediated superoxide production (15). Therefore, 
regulation of monocyte functioning might be due to balanced cytokinc-mediated 
pathways. In addition, effector cells like tonsil-derived В cells, EBV-B cells or 
В cell lines like Daudi that express I1FC7RII isoforms are unable to perform 
hFc7RII-mediated killing even when cells have been preincubated with a 
cytokine-cocktail of IL2, IL4, IL6 and IFN7 (100). These data indicate that 
hFc7RII-mediated functions are dependent on isoform and cell type. 
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Table 3. General characteristics of human FcyRII 
Cluster Differentiation 
Protein (kDa) 
CD32 
Fc7RIIa: 40 
FcvRIIb: 40 
Fc^RIIc: 40 
Cellular distribution monocytes/macrophages; neutrophils; 
В cells; platelets; eosinophils; basophils; 
Langerhans cells; syncytiotrophoblasts; 
placental phagocytes and endothelial cells 
Polymorphism 
Ligand binding and rankorder 
Affinity for hlgG (Ka) 
Protein structure 
Signal transducing proteins 
Gene localization (chromosome) 
Number of genes; isoforms 
(TM: transmembrane receptor) 
FC7RIIA: 
70% mlgGl-HR/ hIgG2-LR 
hlgG: 3 > 1 = 2 > > > 4 ; 
mlgG: 1 >2b> > > 2 a = 3 ; 
rabbit IgG; bovine IgGl; 
10* м-' 
single chain 
2 Ig-like domains 
unknown 
1 q23-24 
3 genes; 7 isoforms 
Fc7RIIal-HR ; TM 
Fc7RIIal-LR 
Fc7RIIbl 
Fc7RIIb2 
Fc7RIIb3 
FC7RIIC 
sFc7RIIa2 
TM 
TM 
TM 
TM 
TM 
soluble 
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Polymorphism in hFcyRII: A functional polymorphism has been detected 
initially in the mlgGl anti-CD3 mAb induced Τ cell proliferation assay (Figure 
3) in which peripheral human blood monocytes function as accessory cells, 
defining high- (HR) and low-responder (LR) individuals to mlgGl (70% and 
30%, respectively) (29,154,156). This polymorphism in hFcyRII is also evident 
in platelets (92) and neutrophils (17). Three phenotypes could be detected 
biochemically in isoelectric focusing of hFc7RII suggesting codominant 
expression of two I1FC7RII alleles (7). The polymorphism is additionally 
reflected in binding of mlgGl sensitized human red blood cells (EA-mlgGl 
rosetting) (172), immunofluorescence with anti-Fc7RII mAb 41H.16 (56), 
ADCC against mlgGl-coated target cells (20) and release of IL2, IFN7 (52), 
TNFa (36) and IL6 (82) after binding of mlgGl antibodies to hFciRII. 
Moreover, in mlgGl-HR individuals high-affinity binding of mlgGl is 
associated with low-affinity binding of hIgG2, and vice versa (183). The high-
affinity binding of hIgG2 to the hFc7RII-LR isoform is confirmed in functional 
studies and is present on monocytes, neutrophils and platelets (113,114). 
Molecular structure of hFcyRII: Due to FcR-gene duplication, recombination 
and mutation several structurally related low-affinity FC7R genes have evolved 
(127), and differential RNA splicing events result in multiple FC7R isoforms. 
Until now, three genes (hFcyRIIA, В and C) have been characterized encoding 
hFc7RIIal, hFc7RIIa2, hFc7RIIbl, hFc7RIIb2, hFc7RHb3 and I1FC7RIIC 
transcripts (23,169). The genomic organization of the I1FC7RII gene, that is 
located on chromosome 1 (127,134), shows structural homology with HLA 
class I and II genes (43) encoding Ig-like domains as observed in other 
members of the immunoglobulin gene superfamily. 
The extracellular domains of the hFc7RIIal and hFc7RIIb (bl, b2 or b3) 
encoded proteins differ in 7 amino acid (aa) residues (149). The hFc7RIIal 
isoform expressed on monocytes and myeloid cells and its functioning have 
been reported previously as low-affinity I1FC7R (71,91); this isoform is also 
detected on neutrophils, platelets, human placental cells and cell lines U937, 
HL60 and K562 (21,61,149). The mlgGl-polymorphism that has been described 
is defined by substitution of only one aa at position 131 of hFc7RIIal (61). 
Polymorphism of hFc7RIIal at position 27 has also been described (153,182) 
but only the residue at position 131 (Arg in mlgGl-HR, His in mlgGl-LR) is 
involved in the functional polymorphism (26,27,153,181). 
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The hFc7RIIb2 transcript (21,42,143,184) is present in human В cells, cultured 
monocytes, neutrophils and placental trophoblasts and cell lines U937, Daudi 
and Raji (but not K562). The isolated hFc7RIIb2 transcript has >95% 
homology with hFc7RIIal and encodes three possible N-linked glycosylation 
sites (21,42,143). Furthermore, the hFcyRIIbl and hFc7RIIb2 encoded proteins 
have similar cytoplasmic regions except for a 19 aa-encoded insert in 
hFc7RIIbl (21,184). Differential functions related to this insert have not yet 
been defined but have been studied in detail in the murine system. The 
mFcyRIIbl (mainly on В lymphoid cells) and mFc7RIIb2 (mainly on 
macrophages) encoded proteins are identical except for a 47 aa insert in the 
cytoplasmic region of mFc7RIIbl. Functional studies on transfected cells have 
revealed that mFc7RIIbl is involved in binding of immune complexes, capping, 
and intracellular^ binding of actin whereas mFc7RIIb2 mediates endocytosis 
of antigen-antibody complexes, internalization via coated pits, antigen 
presentation, phagocytosis of IgG-coated particles, and ADCC (53,54,106). A 
conserved region of at least 10 aa is disrupted by the insert in mFc7RIIbl and 
this actively prevents endocytosis via coated pit localization (105). 
The I1FC7RIIC gene (previously also named hFc7RIIa') has possibly evolved 
from a cross-over event of the hFc7RIIA and I1FC7RIIB gene at an exon/intron 
break. Exons of the В gene encode the extracellular, the transmembrane region 
and the first 8 - 1 0 amino acids of the cytoplasmic region (>99% identity) 
(21,44,149) whereas the remaining part of the cytoplasmic region of hFc7RIIC 
gene product is encoded by exons from the A gene (>95% identity). The 
protein is expressed on placental syncytiothrophoblasts in high amounts and also 
on monocytes, В cells, neutrophils and cell lines U937, Daudi and Raji, but not 
on human Τ cells or cell line K562 (21,149). 
Signal transduction via hFcyRII: Binding studies on the hFc7RIIal encoded 
protein revealed that binding of mlgGl or anti-Fc7RII mAb Г .З or KuFc79 
does not require extracellularly N-linked glycosylation or the presence of a 
cytoplasmic domain (116). However, two tyrosine residues within the 
cytoplasmic domain encoded by hFc7RIIal transcripts are essential in mediating 
calcium responses, cytolytic activity and phagocytosis (79,108). In platelets, 
cross-linking of hFc7RIIal initiates calcium responses (9) and also tyrosine 
phosphorylation (via src-related tyrosine kinases) of hFc7RIIal itself (62). 
Binding studies on cells transfected with hFc7RIIbl revealed that anti-CD32 
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mAb KB61, KuFc79, 41H.16 and AT10 (58) bind to these cells whereas no 
binding is observed with anti-CD32 mAb IV.3, 2E1, CIKM3 or CIKM5. 
Furthermore, EA-rosetting with mlgGl, mIgG2a and mIgG2b sensitized RBC 
(Figure 1) occurs when rosetting is performed at 37 °C. In addition, mlgG and 
hlgG of all isotypes except mIgG3 and hIgG2 are able to induce anti-CD3 mAb 
induced Τ cell proliferation in the presence of hFcyRIIbl -positive accessory 
cells; this response is completely inhibited by mAb 41H.16 (184). With respect 
to data obtained with transfected cells, however, one should keep in mind that 
very high numbers of FcR are expressed on these cells. Differences in ligand 
affinity can be also be obscured when very high amounts of mlgGl anti-CD3 
mAb (29) or erythrocytes highly sensitized with mlgGl mAb (153) are used in 
functional studies. 
Signal transduction mediated by hFc7RIIA, В and С gene encoded receptors has 
not yet been studied as extensively as in the murine system, but the conserved 
region of 10 aa that encodes endocytosis and formation of coated pits in 
mFc7RIIb2 is also present in hFc7RIIB gene products (21,54,105). Further 
investigations on functions mediated by hFc7RII isoforms expressed on different 
types of cells are required to elucidate the specific intracellular transducing 
pathways. 
The human low-affinity Fc receptor for IgG; hFc7RIII; CD16 
General expression of hFcyRIII: The human low-affinity FC7RIII (Table 4) is 
mainly expressed on macrophages and neutrophils (but not on В cells) and is 
the only FcR expressed on NK cells (128,167). Soluble hFc7RIII molecules 
released from neutrophils are detectable at a high concentration in human 
plasma (64). No expression of hFc^RIII is measured on normal monocytes but 
this FcR can be induced by incubation during a few hours with transforming 
growth factor-beta (TGF/3) (186). The hFc7RIII is also expressed on monocytes 
that have been cultured in vitro for several days (28), and on macrophages. 
Since hFc7RIII isoforms are absent from the cells (normal monocytes and EBV-
B cells) studied in this thesis no further introduction on this receptor will be 
given. The molecular heterogeneity and biological functioning of the hFc7RIII 
has recently been reviewed (169). 
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Table 4. General characteristics of 
Cluster Differentiation 
Protein (kDa) 
Cellular distribution 
Polymorphism 
Ligand binding and rankorder 
Affinity for hlgG (Ka) 
Protein structure 
Signal transducing proteins 
Gene localization (chromosome) 
Number of genes; isoforms 
(TM: transmembrane receptor) 
18 
Fc-yRIII 
CD16 
FcTRIIIa: 67 
Fc7RIIIb-NAlNAl: 50 - 65 
FcYRIIIb-NA2NA2: 65 - 80 
neutrophils: Fc7RIIIb (TNF-al); 
monocytes: Fc7RIIIa (after TGF/3); 
NK cells and macrophages: Fc7RIIIa 
Fc7RIIIb-NAl isoform: 46% 
Fc7RIIIb-NA2 isoform: 88% 
hlgG: 1 = 3 > > > 2 = 4 ; 
mlgG: 3>2a>2b> > > 1 ; 
rabbit IgG 
\QfUx 
single chain 
2 Ig-like domains 
FcyRIIIa 
associated y- and/or {"-chains 
FCYRIIIA: 1 q23-24 
FcyRIIIB: 1 q23-24 
y- and f-chain: 1 q 
1 gene; 3 isoforms 
Fc7RIHa ; TM 
FeyRIIIb ; GPI-linked 
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HUMAN Fe RECEPTORS FOR IgE; hF«R 
Two FceR molecules have been reported that differ in their cellular distribution 
and binding affinity. The high-affinity FcR for IgE (FceRI) found on basophils 
is trypsin-resistant (147) whereas a low-affinity FcR for IgE (FceRII) (Table 5) 
is expressed on lymphocytes and macrophages, and appears to be trypsin-
sensitive (8,147). Because of the expression of hFceRII on monocytes and В 
cells, this type of Fc receptor will be discussed in more detail. The hFceRII 
also appears of interest since a complete blockade of functioning of the FcR for 
mIgG2b by HLA class II molecules is described in this thesis, and an 
association of hFceRII and HLA-DR antigens has been reported (19). 
The human low-affinity Fc receptor for IgE; hFceRII; CD23 
General expression of hFceRII: The human FceRII/CD23 is constitutively 
expressed on В cells and inducible on monocytes, macrophages, eosinophils, 
platelets, Τ cells and Langerhans cells (32,38). The hFceRII is involved (in a 
cell type dependent way) in regulation of IgE synthesis and В cell development, 
phagocytosis of IgE-coated particles, IgE-dependent cytotoxicity against 
parasites, and release of leukotrienes and other inflammatory mediators 
(37,191). Furthermore, FceRII was described to be identical to the В cell 
differentiation antigen, CD23 (18,194). 
General structure in relation to other FcR molecules: In human and mice, 
surface (s) IgM+/sIgD+ mature В cells express the FceRII molecule which is 
lost after isotype switching to slgG, slgA or slgE (73). The FceRII consists of 
a single chain glycoprotein anchored in the cellular membrane by a single 
transmembrane region in an unusual membrane orientation: the COOH-terminus 
of the protein is oriented extracellularly whereas the NH2-terminus is located 
intracellularly. Preliminary studies on molecular structure have demonstrated 
that some members of the C-type lectin family including FceRII exist as dimers 
at the cell surface (14). In contrast to the carbohydrate-lectin interaction 
suggested by the homology to the lectin-family, ligand-receptor interactions (IgE 
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and FceRII, respectively) do not involve carbohydrates since deglycosylated IgE 
binds well to the FceRII (129,179). 
Table S. General characteristics of human FceRII 
Cluster Differentiation CD23 
Protein (kDa) 45 
Cellular distribution FceRIIa: В cells; 
FceRIIb: after IL4 on В cells, monocytes 
and eosinophils 
Polymorphism no 
Ligand binding and rankorder hlgE 
mlgE 
Affinity for hlgE (Ka) 
кем
1 
Protein structure single chain 
lectin-like domain 
Signal transducing proteins unknown 
Gene localization (chromosome) 19 
Number of genes; isoforms 
(TM: transmembrane receptor) 
1 gene; 2 isoforms: A en В 
FceRIIa 
FciRIIb 
; TM 
;TM 
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Molecular structure of hFceRIl: The molecular structure of the lymphocyte 
hFciRII was first elucidated by using cDNA cloning techniques and studies on 
CD23-transfected eukaryotic cells. Two isoforms from the single copy gene of 
hFceRIl have been described (32,38). The hFceRIIa encoded protein is 
constitutively expressed on В cells whereas the hFceRIIb encoded molecule is 
present on peripheral blood lymphocytes from atopic patients and inducible by 
IL4 on normal В cells, monocytes, and eosinophils (192). In addition, in Un­
treated В cells (38) the expression of hFceRIIb is downregulated by IFN7 
within a short time (one hour) via the inhibition of newly synthesized CD23 
proteins (88). Regulation by IFN> of monocyte hFceRIIb expression is still 
controversial (130). 
Signal transduction via hFceRIl: The hFceRIl proteins were demonstrated to be 
similar in their extracellular regions and an internal cleavage site sensitive to 
trypsin-like proteases has been observed (38). However, the intracellular 
domains of the hFceRIIa and hFceRIIb isoforms vary at 7 aa which causes 
functional differences in signal transduction (192). The hFceRIIa isoform 
encodes a tyrosine residue (instead of a serine residue in FceRIIb) which is 
required for FceRIIa-mediated endocytosis of soluble IgE-complexes in В cells. 
Additionally, a tyrosine kinase of the src-family was found to be physically 
associated with hFceRIIa in activated В cells (151). Furthermore, the hFceRIIb 
isoform encodes an asparagine and a proline residue near the N-terminus which 
are critical in phagocytosis of IgE-coated particles (38,193). Association of 
hFceRIl with signal transducing molecules has not yet been reported. 
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AIM OF THIS STUDY 
In the early 1980s monoclonal antibodies were introduced in the clinic: as 
immunosuppressive agents, e.g. anti-CD3 m Ab, in the treatment of renal 
allograft rejection (33), and for tumor specific cancer therapy (148). However, 
despite the immunosuppressive effect of anti-CD3 mAb, these (murine) 
antibodies caused severe side effects such as fever, headache, nausea and 
diarrhoea (78,160) which later appeared to be related to interactions between 
the Fc part of the murine Ig molecule and human Fc receptors. In vitro studies 
showed that in ADCC mediated by macrophages or killer (K) cells, mIgG2a 
mAb seemed to be most effective whereas less activity was observed with 
mIgG2b or mlgGl mAb (77,148). Later studies revealed that in man, mIgG2a 
mAb predominantly interact with the high-affinity I1FC7RI whereas mlgGl mAb 
cross-reacts with the polymorphic IIFCYRII as described above. Much less 
information was available with respect to cross-reactivity of mIgG2b antibodies 
with human Fc receptors. 
In the mouse, binding of mIgG2b antibodies is mediated by the low-affinity 
FcR, mFc7RII and mFc7RIII (128), whereas hFc7RII was shown to bind 
mIgG2b antibodies under certain conditions. Binding of aggregated mIgG2b is 
enhanced at low ionic strength, is inhibited by anti-Fc7RII mAb, and is trypsin-
resistant (71). Further evidence for the presence of a human FcR that interacts 
with mIgG2b antibodies was found with Τ cell proliferation assays. Similar to 
the polymorphism described for mlgGl, mIgG2b anti-CD3 mAb-mediated 
polymorphic responses of human PBMC have been reported that were 
independent from the mlgGl polymorphism (157); later, this observation has 
been confirmed by other investigators (138,146,175). Therefore, the interaction 
of mIgG2b with human FcR-positive cells on PBMC apparently does not 
involve the Iigand binding site for mlgGl. During several years, the low 
prevalence of mIgG2b-HR individuals has impeded further studies. 
Nevertheless, characterization at the cellular and functional level of the human 
Fc receptor cross-reactive with mIgG2b antibodies is required when mIgG2b 
mAb are to be used immunotherapeutically. 
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The aim of the present study was to investigate the (polymorphic) interaction 
of human Fc receptors with murine mIgG2b antibodies, and to compare the 
mIgG2b-related polymorphism with the previously described polymorphism with 
respect to binding of mlgGl. More specifically, the following questions were 
studied: 
- Which human blood cells are able to support the Τ cell proliferation induced 
by mIgG2b anti-CD3 mAb? 
- Is the polymorphism in the binding of mIgG2b mediated by IIFCYRII? 
- Is hFceRII involved in binding mIgG2b immunoglobulins? 
- Do HLA class II molecules affect functions mediated by the FcR for mIgG2b? 
- Does proteolytic treatment affect the binding of mIgG2b to the FcR for 
mIgG2b? 
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ABSTRACT 
Human (Fc7RI-positive) monocytes are required as accessory cells when Τ cell 
proliferation is induced by murine IgG2a anti-CD3 monoclonal antibodies 
(mAb). This Τ cell proliferation assay provides a sensitive method for detecting 
the presence of monocytes (less than 1 % of monocytes can be detected), and we 
have used it to monitor the effectiveness of different procedures for the removal 
of monocytes from peripheral blood mononuclear cells. Counterflow 
centrifugation, phagocytosis of carbonyl-iron, adherence to plastic, monocyte 
depletion with magnetic beads (Dynabeads M450), and panning with anti-CD 14 
antibodies, each strongly reduced the number of monocytes. However, none of 
these methods, when used on their own, were capable of completely abolishing 
the mitogenic response to murine IgG2a anti-CD3 mAb. A virtually complete 
depletion of monocytes was obtained when the panning procedure using anti-
CD14 antibodies was combined with phagocytosis of carbonyl-iron. 
Importantly, this method could also be used with cryopreserved cells. 
We have applied this improved method for the removal of monocytes, to study 
Τ cell proliferation induced by murine IgG2b anti-CD3 mAb. We were able to 
demonstrate with this model that cells other than monocytes were able to 
provide accessory function. 
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INTRODUCTION 
Many methods are available to remove most monocytes from a suspension of 
peripheral blood mononuclear cells, e.g. adherence (11), panning using anti-
monocyte mAb (4) or human gamma globulin (5), counterflow centrifugation 
(6), phagocytosis of carbonyl-iron (5), or elimination with magnetic beads (e.g. 
Dynabeads M450). It has been noted before, however, that it is very difficult 
to deplete monocytes to such an extent that the mitogenic effect of anti-CD3 
mAb, which is dependent on monocyte Fc receptors (14,15), is completely 
abolished. The presence of only a few monocytes is sufficient to provide the 
accessory function in this Τ cell proliferation assay. It is therefore a very 
sensitive method for measuring small contaminations with accessory cells, the 
presence of less than 1% of Fc7RI-positive cells (i.e., monocytes) being 
detectable. In a recent study we have described an FcyR for mouse IgG2b, 
which is polymorphic and present on human mononuclear cells (10). In order 
to study whether cells other than monocytes are able to provide accessory 
function for Τ cell proliferation induced by mIgG2b anti-CD3 mAb, we needed 
a method for the complete removal of monocytes from (cryo-preserved) 
mononuclear cells. None of the methods mentioned above was, in our hands, 
capable of depleting monocytes to such an extent that the Fc7RI-dependent 
mitogenic effect of mIgG2a anti-CD3 mAb was completely abolished. 
Therefore, we developed a new depletion technique which is based on the 
monocyte-specificity of anti-CD14 mAb. CD14 is a 55 kDa glycoprotein, 
anchored by phosphatidylinositol (PI) to the surface of monocytes and 
macrophages (8,13). We now demonstrate that, using panning with WT14 (anti-
CD14) in combination with phagocytosis of carbonyl-iron, we were able to 
reproducibly obtain a complete depletion of monocytes even when 
cryopreserved mononuclear cells were used. 
MATERIALS AND METHODS 
Cells: Peripheral blood mononuclear cells (PBMC) were obtained from buffycoats of healthy 
donors by centrifugation on a Ficoll-Hypaque gradient (density 1.077 g/ml, Pharmacia, 
Sweden). PBMC were used directly or were cryopreserved and used later. The recovery and 
viability of the cryopreserved cells were >70% and >95%, respectively. 
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Monoclonal antibodies: The following anti-CDU mAb were used for the panning of 
monocytes: 63D3 (hybridoma cell line obtained from American Type Culture Collection, 
Rockville, MD); FMC17, Seralab, Sussex, UK; AML 2-23, Medarex, West-Lebanon, NH; 
and WT14, produced in our laboratory (3). Using a sandwich-ELISA procedure based on a 
technique described by Bazil et al. (1), we were able to demonstrate that these four anti-
C D U mAbs recognize four different and independent epitopes on the C D U antigen 
(manuscript in preparation). In addition, anti-CD 14 mAb anti-Leu-M3 (Becton Dickinson, 
Mountain View, CA) and mAb 197 (directed against CD64, the Fc? receptor type I), that 
was obtained from Medarex, were used in immunofluorescence studies. 
Elimination of monocytes: Several procedures were tested for eliminating monocytes from 
a freshly isolated or cryopreserved mononuclear cell suspension. 
- Counterflow centrifugation: A lymphocyte-enriched (monocyte-depleted) cell suspension 
was obtained from PBMC by counterflow centrifugation (6). Cells were cryopreserved, and 
used later in the Τ cell proliferation assay. 
- Phagocytosis of carbonyl-iron: PBMC were suspended in culture medium (RPMI-FCS) 
which consisted of RPMI-1640 medium (Gibco BRL) containing both Hepes and sodium 
bicarbonate, supplemented with 10% heat-inactivated FCS, 2 mM glutamine, 1 mM sodium 
pyruvate, 50 pg/ml streptomycin and 50 IU/ml penicillin. PBMC (at 5 - 10 χ 10* cells/ml) 
were then incubated with 40 mg/ml carbonyl-iron powder at 37 °C for 1 hr while thoroughly 
resuspending the cell suspension every 10 min. The monocytes that had phagocytosed the 
carbonyl-iron were removed with a magnet. 
- Adherence to plastic: PBMC (1 χ IO4 cells/ml) were incubated in RPMI-FCS in a 75 cm2 
incubation flask at 37 "C and 5% C0 2 , for 45 min. This procedure was repeated one to three 
times with the non-adherent fraction of the PBMC. 
- Dynabeads M450 (Dynal): Because of the presence of FcyR, monocytes are able to bind 
to beads coated with IgG. Immunomagnetic beads coated with sheep anti-mouse IgG 
(Dynabeads M450, Dynal, Oslo, Norway) were incubated with PBMC (2.5 χ 10* cells/ml) 
at a bead concentration of 107 beads/ml at 37 °С for 60 min. with thoroughly resuspension 
of the cell suspension every 10 min. The rosettes of Dynabeads M450 and monocytes were 
eliminated by a magnet (according to the protocol provided by the manufacturer). 
- Panning with anti-CDU mAb: A petri dish was coated with affinity purified, Fc-specific, 
goat anti-mouse IgG (Cappel, Malvern, USA) at 4 °C for 18 h, and then incubated with 1% 
gelatin (as a blocking agent) in PBS at 37 °C for 2 hr. PBMC, 3 - 5 χ 10* cells/ml were 
incubated at 4 °C for 1 hr with a mixture of anti-CDU mAb (63D3, FMC17, AML 2-23 and 
WT14) or WT14 alone at saturating concentrations, washed twice and resuspended in RPMI-
FCS. CDU-positive cells were then removed from the PBMC by capturing them on a dish 
coated with anti-mouse antibodies (1 hr at 37 °C). 
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In all cases, the cells remaining after the monocyte depletion procedure were tested in the 
mIgG2a anti-CD3 induced Τ cell proliferation assay. In several experiments, the percentage 
of contaminating monocytes was evaluated by FACS analysis. In some experiments, as 
described in the results and discussion section, a combination of depletion procedures was 
used. 
Τ cell proliferation assay: The mIgG2a anti-CD3 induced Τ cell proliferation was measured 
by a standard [3H]-thymidine incorporation assay (14) using either PBMC, or monocyte-
depleted cell suspensions obtained from the procedures described above, or a mixture of 
purified Τ lymphocytes and graded numbers of purified monocytes. Τ lymphocytes were 
purified from PBMC by counterflow centrifugation (6) followed by resetting with sheep 
erythrocytes that had been treated with aminoethyl-isothiouronium bromide (2). These 
purified Τ lymphocytes were cryopreserved and used later in the Τ cell proliferation assay. 
Purified monocytes were also obtained by counterflow centrifugation and used after 
cryopreservation. 10s PBMC or monocyte-depleted cells (or 10s purified Τ cells and various 
numbers of monocytes) were incubated in RPMI-FCS with anti-CD3 mAb (WT32, 50 ng/ml) 
at 37 °C in a humidified atmosphere of 5% C0 2 in air for 72 hr in U-bottomed microtitre 
wells. During the last 18 hr of the incubation period [3H]-thymidine (1.85 χ IO4 Bq/well) was 
present. Experiments were carried out in triplicate. The stimulation-index (SI) was calculated 
by dividing counts per minute (c.p.m.) obtained in the presence of anti-CD3 mAb by c.p.m. 
obtained in its absence. 
Immunofluorescence: 5 χ IO5 cells were incubated with mIgG2a mAb 197 or mIgG2b mAb 
anti-Leu-M3 (or no mAb for controls) at 4 °C for 30 min., washed in PBS containing 1% 
bovine serum albumin and 0.1% NaN3, labelled with FITC-conjugated subclass-specific 
F(ab')2 fragments of goat anti-mouse IgG (Southern Biotechnology Associates, Birmingham, 
AL), and measured in a Coulter Epics flow cytometer. In each sample the fluorescence 
intensity from 5000 cells was quantified. 
RESULTS AND DISCUSSION 
Sensitivity of the readout method 
The Τ cell proliferation assay induced by mIgG2a anti-CD3 mAb is dependent 
on the presence of FcYRI-positive accessory cells. In previous experiments we 
had found that in the presence of 20% monocytes, a concentration of 50 ng/ml 
of WT32 (IgG2a anti-CD3 mAb) results in optimal Τ cell proliferation. We 
subsequently determined the percentage of contaminating monocytes that is able 
to induce a detectable Τ cell response in the presence of 50 ng/ml of IgG2a 
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anti-CD3 mAb (Figure 1). When 1000 monocytes were added to 105 purified 
Τ cells, there was already a measurable proliferative response to mIgG2a anti-
CD3 mAb (605 ± 287 c.p.m.; SI = 15). Therefore, the presence of 1% 
contaminating monocytes can be detected using this assay. Optimal Τ cell 
proliferation was obtained when 5000 monocytes per IO5 Τ cells were present. 
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Proliferation of purified Τ cells (1 χ 10s cells/well) stimulated with mIgG2a anti-CD3 mAb 
(WT32, 50 ng/ml) in the presence of increasing numbers of autologous monocytes (0 - 2 χ 
IO4 cells). Results are expressed as stimulation indices. At an optimal concentration of 
monocytes (2 χ 10*), [5H]-thymidine incorporation was 77,911 + 4,881 c.p.m. 
Monocyte depletion obtained with different procedures 
Removal of monocytes by any of the procedures described above caused a 
significant reduction of monocytes as evidenced by a decreased mitogenic 
response to mIgG2a anti-CD3 mAb. Τ cell proliferation measured after 
monocyte depletion was compared with Τ cell proliferation obtained with the 
untreated suspension of PBMC, and is expressed as a percentage of the value 
obtained with untreated PBMC. The extent of monocyte depletion varied 
between different experiments, but was never complete with any of the 
depletion procedures when used on its own (Table 1). 
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Table 1. 
Removal of monocytes from freshly isolated or cryopreserved PBMC by different 
procedures 
Method of elimination 
Untreated 
Counterflow centrifugation 
Carbonyl-iron 
Adherence to plastic 
Dynabeads M4S0 
Panning with mAb mixture 
Panning with WT14 
Proliferation of mononuclear cells 
Freshly isolated 
% of control 
100. 
31 ± 18 
32 ± 30 
36 ± 13 
48 ± 12 
57 ± 18 
63 ± 20 
n' 
16 
4 
3 
4 
2 
4 
3 
Cryopreserved 
% of control η 
100 16 
NDb 
ND 
80 ± 5 3 
ND 
29 ± 26 6 
3 6 + 1 7 3 
a) n: number of experiments 
b) ND: not determined. 
It is noteworthy that adherence to plastic, which is a common procedure for 
monocyte depletion, yielded unsatisfactory results, especially when applied to 
cryopreserved cells. FACS analysis showed that, with cryopreserved cells, the 
percentage of FcYRI-positive cells (stained with mAb 197) decreased from 
23.3% to 11.2% after adherence, and the percentage of CD14-positive cells 
(stained with anti-Leu-M3) decreased from 19.9% to 8.3%. It has been 
demonstrated before that significant numbers of monocytes are non-adherent 
(7,11). Chehimi et al. (5) have compared several methods for the removal of 
monocytes, and concluded that combinations of adherence and phagocytosis of 
carbonyl-iron or adherence and panning over plates coated with immunoglobulin 
were insufficient to remove all monocytes. Only a combination of four depletion 
methods proved to be effective in their hands. Similarly, Ceuppens and Baroja 
(4) had to use a combination of E-rosetting, panning with an anti-monocyte 
mAb, and leucine methylester in order to obtain Τ cell suspensions that were 
completely devoid of accessory cells. With cryopreserved cells, we observed 
that panning with anti-CD14 mAb WT14 yielded better results than adherence, 
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although monocyte depletion was apparently still not complete (Table 1). Using 
FACS analysis, Fc7RI-positive cells decreased from 26.4% to 2.6% (CD14-
positive cells from 26.7% to 2.7%) after panning with WT14. The anti-CD14 
mAb has been used before, with rabbit complement, as one of the steps in the 
removal of monocytes (5). The CD 14 antigen appears to be important for 
monocyte function (12,16) and we have previously demonstrated that mAb 
WT14, which is directed against CD14, can be used in immunohistology as a 
diagnostic marker for macrophage infiltration during acute interstitial rejection 
of renal allografts (3). Although one might have expected that in a panning 
procedure a mixture of mAb, recognizing different epitopes on the CD14 
antigen, would be more effective than using only one mAb, this appeared to be 
not the case since mAb WT14 was equally effective as a mixture of anti-CD14 
mAb in our hands (Table 1). The failure to accomplish complete elimination of 
monocytes with the panning procedure alone using (a mixture of) anti-CD 14 
m Abs, may be related to heterogeneity of CD14 expression. It is of interest to 
note that a CD14-negative subset of monocytes has been described (9). 
Monocyte depletion by a combination of two elimination procedures 
None of the methods mentioned above was successful, when used separately, 
in obtaining complete elimination of the accessory monocytes that supported the 
mIgG2a anti-CD3 induced Τ cell proliferation. Since panning with anti-CD 14 
mAb reproducibly caused, by itself, a significant reduction in monocyte 
numbers (especially when cryopreserved mononuclear cells were used), we 
decided to test this method in combination with the phagocytosis of carbonyl-
iron. First, PBMC were incubated with a mixture of anti-CD14 mAb or WT14 
alone and most of the CD14-positive cells were removed by panning on a petri 
dish coated with (Fc-specific) goat anti-mouse IgG. The remaining cells (still 
containing 2-3% monocytes as mentioned above) were subsequently incubated 
with carbonyl-iron, and the phagocytic cells were removed by a magnet. The 
results are shown in Figure 2. When a combination of panning with a mixture 
of anti-CD14 mAbs (or WT14 alone) and phagocytosis of carbonyl-iron was 
applied to freshly isolated PBMC, a reproducible reduction of 97 ± 2% (n=4) 
and 98 ± 1% (n=2), respectively, of the mIgG2a anti-CD3 induced Τ cell 
proliferation was achieved. Therefore, panning with a mixture of anti-CD 14 
mAbs (or WT14 alone) followed by phagocytosis of carbonyl-iron consistently 
resulted in a virtually complete elimination of monocytes. The observed 
reduction of Τ cell proliferation could not be ascribed to some nonspecific toxic 
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effect of the depletion procedure, since the remaining cell suspension was still 
able to proliferate in response to mIgG2a anti-CD3 mAb when purified 
monocytes were added (Figure 2). 
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Figure 2. 
Elimination of monocytes and macrophages from freshly isolated or cryopreserved PBMC. 
Results are expressed as a percentage of the Τ cell proliferation obtained with untreated cells 
(open bars). Monocytes were depleted by the combination of panning with a mixture of anti-
CD 14 mAb and phagocytosis of carbonyl-iron (shaded bars), or by a combination of panning 
with WT14 alone and phagocytosis of carbonyl-iron (black bars). In some experiments, 
monocytes were added again (to a final concentration of 20%), after depletion by panning 
with WT14 plus carbonyl-iron (cross-hatched bar). The figure contains the combined data 
from a total of 16 experiments. Τ cell proliferation obtained with untreated PBMC ranged 
from 13,591 to 57,834 c.p.m. 
It is important to stress that the method described here is also effective in 
depleting monocytes from cryopreserved cell suspensions (Figure 2). This 
conclusion was supported by immunofluorescence studies. After panning with 
WT14 and phagocytosis of carbonyl-iron, the percentage of FcYRI-positive cells 
had decreased from 26.4% to 1.0% (CD14-positive cells from 26.7% to 0.8%). 
In our studies of the FC7R for mIgG2b, we found that only a small percentage 
("mIgG2b high-responders") of normal individuals have a functional receptor 
for this isotype of mouse immunoglobulins, and therefore it is difficult to obtain 
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freshly isolated PBMC. Cryopreservation of cells is very helpful in such 
circumstances. When the monocyte depletion method described above was 
applied to cryopreserved PBMC from nmIgG2b high-responders", a significant 
mitogenic response to mIgG2b anti-CD3 mAb was still observed which 
indicates that cells other than monocytes (presumably В lymphocytes) can 
function as accessory cells in this model (10). 
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ABSTRACT 
With respect to murine (m)IgGl anti-CD3 monoclonal antibody (mAb), a 
polymorphic mitogenic response of peripheral blood mononuclear cells (PBMC) 
has been described which is caused by polymorphism of monocyte FC7RII, and 
which defines high-responders to mlgGl (mlgGl-HR, approximately 70% of 
normal individuals) and low-responders (mlgGl-LR). PBMC also exhibit a 
polymorphic mitogenic response to mIgG2b anti-CD3 mAb. In the present study 
18 out of 550 individuals (3%) were mIgG2b-HR. Purified monocytes from 
mIgG2b-HR were able to support the mitogenic response to mIgG2b anti-CD3 
mAb of purified Τ cells from mIgG2b-LR. Surprisingly, a significant mitogenic 
response to mIgG2b anti-CD3 mAb remained after vigorous depletion of 
monocytes from mIgG2b-HR PBMC. Apparently В cells are responsible for this 
accessory function since Epstein-Barr virus (EBV)-transformed В cells from 
mIgG2b-HR (but not from mIgG2b-LR) were able to support Τ cell 
proliferation induced by mIgG2b anti-CD3 mAb. Only EBV-B cells from 
mIgG2b-HR were able to form rosettes with human red blood cells (RBC) that 
had been sensitized with mIgG2b anti-glycophorin A mAb (EA-mIgG2b). These 
EBV-B cells did not express FC7RI or FC7RIII, and could bind some but not 
all anti-Fc7RII mAb. The mitogenic response to mIgG2b anti-CD3 was not 
inhibited by any of the anti-Fc7RII mAb. From these studies we conclude that 
a polymorphic Fc receptor is expressed on human В cells and monocytes, which 
cross-reacts with mIgG2b. This receptor is different from FC7RI and FC7RIII, 
and apparently also from FC7RII. 
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INTRODUCTION 
Fc receptors for IgG (FcyR) are involved in clearing immune complexes, 
phagocytosis, antibody dependent cell-mediated cytotoxicity (ADCC), and can 
act as a trigger molecule for the extracellular release of lysosomal enzymes and 
superoxide production. Until now three classes of human FC7R have been 
described, FC7RI (CD64), FC7RII (CD32) and FC7RIII (CD 16). The 
availability of mAb, and the isolation of cDNA coding for these Fc receptors, 
have rapidly expanded our knowledge of structure and function of human Fc 
receptors (1-5). FC7RI, a 72 kDa glycoprotein with high-affinity for monomeric 
human (h) IgG, is present on monocytes and macrophages from virtually all 
individuals and can be induced on neutrophils after stimulation with interferon-γ 
(IFN7) (6). FC7RII, a 40 kDa glycoprotein with low-affinity for hlgG is present 
on monocytes, macrophages, neutrophils, eosinophils, basophils, platelets and 
В cells. This widely distributed receptor occurs in multiple isoforms (7-9). 
Proteolytic enzymes can significantly enhance the affinity of FC7RII (10,11). 
Another receptor class, FC7RIII (50 - 80 kDa glycoprotein) occurs in two 
forms: a transmembrane form which is found on macrophages and natural killer 
(NK) cells, and a phosphatidylinositolglycan-linked receptor which is abundantly 
expressed on neutrophils (12). 
Human FC7R can also cross-react with mouse IgG. This cross-reactivity may 
become important when mouse monoclonal antibodies (mAb) are used for 
immunotherapy. Major differences between different isotypes of murine IgG 
have been observed with respect to their efficacy to mediate ADCC by human 
monocytes (13) or lymphocytes (14). mIgG2a can bind to FC7RI, whereas 
mlgGl can bind to FC7RII (15). With respect to the binding of mlgGl to 
FC7RII, a polymorphism has been described. This mlgGl polymorphism was 
first observed using mlgGl anti-CD3 mAb in Τ cell proliferation assays, where 
Fc7R-positive cells function as accessory cells. In 70% of Caucasian 
individuals, monocyte FC7RII exhibits strong binding of mlgGl (mlgGl high-
responder, HR) and in 30% of the population this interaction is weak (mlgGl 
low-responder, LR) (4,11,16-18). This polymorphism is also reflected in EA-
mlgGl rosetting (17) and in monocyte ADCC against erythrocytes that have 
been coated with mlgGl antibody (19,20). Three phenotypical isoelectric 
focusing patterns have been found with monocyte FC7RII, indicating homo­
zygous forms of mlgGl-HR, mlgGl-LR and a heterozygous form (21). 
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Allotypic isoforms of this receptor can also be detected using a new anti-Fc7R.II 
m Ab, 41H.16 (22). DNA sequence analysis predicts differences in only one or 
two amino acid residues between mlgGl-HR and mlgGl-LR receptor molecules 
(23,24). 
We and others have previously reported that only a small minority (less than 
10%) of normal human individuals are high-responders with respect to mIgG2b 
(mIgG2b-HR) in the anti-CD3 induced Τ cell proliferation assay (18,25-28). 
Remarkably, the Τ cell proliferation induced by mIgG2b anti-CD3 in mIgG2b-
HR is not associated with release of IFN7 or IL2, in contrast to Τ cell 
activation induced by mIgG2a or mlgGl anti-CD3 m Ab (29). This striking 
difference suggests the existence of a completely different Τ cell activation 
pathway associated with binding of the mIgG2b antibody to an Fc receptor 
different from FC7RI or FC7RII. In this study we have therefore tried to 
characterize the FC7R which is reactive with mIgG2b. The results suggest that 
the polymorphic Fc receptor for mIgG2b is present on В cells as well as 
monocytes, and that the binding site for mIgG2b is different from the binding 
site for mlgGl, and might even be located on a different receptor. 
MATERIALS AND METHODS 
Monoclonal antibodies: Anti-Fc7RI mAb 32.2 (mlgGl) and 197 (mIgG2a), and anti-Fc7RII 
m Ab IV.3 (mIgG2b) were obtained from Medarex (West Lebanon, NH). Anti-Fc7RII mAb 
CIKM5 (mlgGl) (30) was a generous gift from dr. G. Pilkington (Peter MacCullem Cancer 
Institute, Melbourne, Australia); anti-Fc7RIII mAb, Leu 11a (mlgGl) and Leu l ib (IgM) 
were from Becton Dickinson (Mountain View, CA). The mAb KB61 (mlgGl) (31) and 
41H.16 (mIgG2a) (32) were kindly provided by Drs. D.Y. Mason (John Radcliffe Hospital, 
Oxford, U.K.) and Th.F. Zipf (Anderson Hospital and Tumor Institute, Houston, TX), 
respectively. These last two mAb were included in the CD32 cluster during the Fourth 
Leucocyte Workshop (Vienna, 1989) but, in contrast to IV.3 and CIKM5, these two mAb 
recognize an isoform of the CD32 antigen that is expressed preferentially on В lymphoid 
cells (31,32). Anti-CD3 mAb SPV-T3a (33) was a kind gift from Dr. H. Spits (DNAX, Palo 
Alto, CA). Anti-CD3 mAb WT32 (16) and anti-T cell receptor (TcR) mAb WT31 (16,34) 
were developed in our own laboratory. The following anti-CD 14 mAb were used: 63D3 (cell 
line obtained from American Type Culture Collection, Rockville, MD), FMC17 (Seralab, 
Sussex, U.K.), AML-2-23 (Medarex) and WT14 (from our own laboratory) (35). A mIgG2b 
anti-glycophorin A mAb was generously provided by Dr. L. Aarden (CLB, Amsterdam, The 
Netherlands). 
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Monocytes: Peripheral blood mononuclear cells (PBMC) were obtained from buffy coats or 
from leucocytes isolated by cytapheresis from healthy donors, by centrifugation on a Ficoll-
Hypaque gradient (Pharmacia, Uppsala, Sweden). Monocytes were isolated from PBMC by 
counterflow centrifugation (36) and were > 9 0 % pure, as judged by staining with May-
Grunwald-Giemsa and for non-specific esterase. PBMC and purified monocytes were 
cryopreserved and used later. The recovery and viability of the cryopreserved cells was 
> 70% and >95%, respectively. 
Τ lymphocytes: Lymphocytes were purified from PBMC by counterflow centrifugation. Τ 
lymphocytes were isolated from this suspension by resetting with sheep erythrocytes treated 
with aminoethylisothiouronium bromide (37). The purified Τ lymphocytes were cryo­
preserved and used later. 
EBV-transformed В cell lines: Cryopreserved PBMC from some mIgG2b-HR or -LR 
individuals were used for Epstein-Ватт virus (EBV) transformation of the В cells. 
Immortalization and stabilization of the cell lines were performed by dr. F. Uytdehaag and 
co-workers at the Department for Public Health (RIVM) at Bilthoven, The Netherlands. 
EBV-transformed В cell lines, human erythromyeloid (K562), myeloid (U937) and B-
lymphoblastoid (Daudi, Raji) cell lines were cultured in RPMI-1640 medium containing 
Hepes and sodium bicarbonate, supplemented with 10% heat-inactivated foetal calf serum 
(FCS), 2 mM glutamine, 1 mM sodium pyruvate and gentamycin (40 μg/ml). Since infection 
of the cells with Mycoplasma species can cause false-positive FcR reactivity (38), the cell 
lines K562, U937, Daudi, Raji, and all the EBV-transformed В cell lines, were tested for 
Mycoplasma infection using the Gen-Probe Mycoplasma Tissue Culture II detection system 
(Gen-Probe, San Diego, CA) which contains a universal DNA-probe that can hybridize all 
known Mycoplasma species. Cell lines that were Afycop/<uma-positive were first treated with 
ciprofloxacin during 14 days (39), and only Mycoplasma-neg&úve cells were used in the 
present study. PBMC, monocytes and EBV-transformed В cell lines were given the same 
identification number as the individual from which they were derived. 
Depletion of monocytes: Depletion of monocytes from PBMC was carried out by using a 
combination of panning with anti-CD14 mAb and phagocytosis of carbonyl-iron. A Petri dish 
was coated with affinity-purified, Fc specific goat-anti-mouse IgG (Cappel, Malvern, PA) 
at 4°C for 18 hr and incubated with 1 % gelatin at 37°C for 2 hr. PBMC (2.5 χ 10* cells/ml) 
were incubated at 4°C for 1 hr with a mixture of anti-CD14 mAb (mAb 63D3, FMC17, 
AML-2-23, and WT14) at saturating concentrations, washed twice and resuspended in RPMI-
1640 containing 10% FCS. After incubating for 1 hr at 37°C in the precoated Petri dish, 
non-adherent cells were removed and incubated (at 5 - 10 χ IO4 cells/ml) with 40 mg/ml 
carbonyl-iron powder for 1 hr at 37°C with thoroughly resuspending the cell suspension 
every 10 min. The monocytes which had phagocytosed the carbonyl-iron were removed 
magnetically. The monocyte-depleted cell suspension did not contain detectable numbers of 
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monocytes as measured in immunofluorescence (using mAb WT14), or seen on a cytospin-
preparation using May-Grunwald-Giemsa staining. 
Τ cell proliferation assay: Τ cell proliferation was measured by a standard [3H]-thymidine 
incorporation assay (16) using either PBMC, or monocytes plus purified autologous Τ cells, 
or EBV-transformed В cells plus purified autologous Τ cells. Cells were incubated with 
mouse anti-CD3 or anti-TcR mAb of different subclasses. Briefly, 1 χ 10s PBMC or 1 χ 10s 
purified Τ cells plus 2 χ IO4 accessory cells (autologous monocytes or EBV-transformed В 
cells) were incubated with anti-CD3 or anti-TcR mAb for 72 hr at 37°C and 5% C0 2 in U-
bottomed microtitre wells. During the last 18 hr of the incubation period [3H]-thymidine 
(1.85 χ 104 Bq/well) was present. Anti-CD3/TcR mAb used were WT32 (mIgG2a) at 50 
ng/ml, SPV-ТЗа (mIgG2b) at 1 μg/ml, or WT31 (mlgGl) at 100 ng/ml. The stimulation-
index (SI) was calculated by dividing counts per minute (c.p.m.) in the presence and absence 
of anti-CD3 mAb. High-responsiveness was defined by a SI > 5. In some experiments anti-
FC7RII mAb (10 /ig/ml) were added at the start of the Τ cell proliferation assay. When EBV-
transformed В cells, or cell lines Daudi, K562, or U937 were used as accessory cells in Τ 
cell proliferation assays, these cells were first irradiated at 60 Gy. All proliferation 
experiments were performed in triplicate at least five times. 
EA-rosetting: Rh(D)-positive human red blood cells (RBC) were sensitized with anli-
glycophorin A mAb of the mIgG2b isotype. EBV-B cells (2x10* cells/ml) were incubated 
for 1 hr at room temperature with 0.5% (vol/vol) sensitized human RBC after centrifugation 
for 4 min. at 20°C (20 χ g). The percentage of rosettes (at least three bound human RBC) 
was scored microscopically. Rosetting at low ionic strength (40) was carried out in a medium 
consisting of a mixture of one part of phosphate-buffered saline (PBS) and two parts of a 5 % 
glucose suspension (pH 7.4). In some experiments we used Rh(D)-positive human RBC 
sensitized with either mlgGl anti-glycophorin A mAb (EA-mlgGl) (a gift from M. Bos, 
CLB, Amsterdam, The Netherlands) or human IgG, a commercially available polyclonal anti-
Rh(D) antiserum containing mainly hIgG3 and hlgGl (Merz & Dade, Dudingen, Switzerland) 
to detect FC7RII or FcyRI, respectively (15). The presented experiments were performed at 
least five times. 
Immunofluorescence assay and flow cytometry: Immunofluorescence studies were carried out 
using standard procedures. Briefly, 5 χ 10s cells were incubated with mAb on ice for 30 
min., washed in PBS containing 1% BSA and 0.1% NaN3, labelled with FITC-conjugated 
F(ab')2 fragments of sheep anti-mouse IgG H&L chain (Cappel, Malvern, PA) and measured 
in an Ortho 50-H flow cytometer. In each sample the fluorescence intensity from 5000 cells 
was quantitated. 
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RESULTS 
Only few individuals are mIgG2b-HR 
In a search for mIgG2b-HR individuals, we performed Τ cell proliferation 
assays in 550 different mononuclear cell suspensions. A proliferative response 
to mIgG2b anti-CD3 mAb was observed with PBMC from 18 (3%) of the tested 
individuals. All the individuals tested responded to mIgG2a anti-CD3, which 
indicates the presence of FC7RI. Table 1 shows the results of the proliferation 
assays of four mIgG2b-HR individuals whom we have studied in detail. These 
four individuals were also high-responder to mlgGl. 
Table 1. 
Anti-CD3 induced Τ cell proliferation in PBMC from four mIgG2b-HR individuals 
(I-IV) 
Stimulation index 
Subclass anti-CD3 mAb I II III IV 
No mAb 1 1 1 1 
mlgGl 22 26 18 22 
mIgG2a 25 56 48 29 
mIgG2b 19 35 48 32 
PBMC (1 χ 10s cells) were incubated with anti-CD3/TcR mAb of different subclass: WT32 
(mIgG2a), 50 ng/ml; SPV-ТЗа (mIgG2b), 1
 Mg/ml or WT31 (mlgGl), 100 ng/ml. In the Τ 
cell proliferation assay [3H]-thymidine incorporation was measured during the last 18 hr of 
the incubation period of 72 hr. The stimulation-index was calculated by dividing c.p.m. 
obtained in the presence and absence of anti-CD3/TcR mAb. The experiments were 
performed in triplicate at least five times. 
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Monocytes can support Τ cell proliferation induced by mIgG2b anti-CD3 
mAb 
We next tested whether high-responsiveness to mIgG2b is a property of the Τ 
cells, or is determined by the accessory cells. Table 2 shows the results of an 
experiment in which monocytes (obtained by elutriation) from a mIgG2b-HR 
or mIgG2b-LR individual were incubated with (non-autologous) Τ cells from 
a mIgG2b-HR or -LR in the presence of mIgG2b anti-CD3 mAb. No Τ cell 
proliferation was seen in the absence of accessory cells, and only monocytes 
from mIgG2b-HR could support the mitogenic response. 
Table 2. 
mIgG2b anti-CD3 induced Τ cell proliferation of purified Τ cells from mIgG2b-HR or 
mIgG2b-LR in the presence of (non-autologous) mIgG2b-HR or mIgG2b-LR monocytes 
Τ cells 
LR 
HR 
LR 
HR 
Monocytes 
LR 
LR 
HR 
HR 
[3H]-Thymidine incorporation 
(c.p.m.) 
No anti-CD3 
54 ± 7 
2,518 ± 682 
99 ± 35 
1,911 ± 413 
+ anti-CD3 
88 ± 23 
785 ± 391 
6,349 ± 655 
13,075 ± 250 
Purified Τ cells (1 χ ΙΟ5 cells) plus purified (non-autologous) monocytes (2 χ 10* cells) from 
mIgG2b-HR or mIgG2b-LR individuals were incubated with mIgG2b anti-CD3 mAb (SPV-
T3a, 1 pg/ml). The [3H]-thymidine incorporation was measured during the last 18 hr of the 
incubation period of 72 hr. Τ cells or monocytes incubated seperately with mIgG2b anti-CD3 
gave no response (< 100 c.p.m.). Values given are means + SD of triplicates. 
In order to further characterize the polymorphic Fc receptor for mIgG2b that 
apparently is present on human monocytes, the anti-Fc7RII mAb IV.3, KB61 
and 41H.16 were tested for inhibition of the mIgG2b anti-CD3 induced 
mitogenic response. Whereas mlgGl anti-CD3 induced Τ cell proliferation 
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could be inhibited almost completely by these antibodies, the mitogenic 
response to mIgG2b anti-CD3 mAb was not inhibited at all (Table 3). Inhibition 
experiments were also performed at lower concentrations of mIgG2b anti-CD3 
(0.1 and 0.01 Mg/ml). Also under these conditions no significant inhibition by 
anti-Fc7RII mAb was observed. At 0.01 μg/ml of mIgG2b anti-CD3, for 
instance, the mean percentage of inhibition observed in three experiments was 
27% for mAb IV.3, 19% for KB61, and 20% for 41H.16. Even the 
combination of mAb Г .З and 41H.16 was not inhibitory for the mIgG2b-
induced response (the percentages of inhibition obtained in three experiments 
were 1%, 5%, and 32%). When instead of PBMC mIgG2b-HR monocytes 
(separated from PBMC by elutriation) plus purified autologous Τ cells were 
used, an identical pattern of inhibition by anti-Fc7RII mAb was observed 
(complete inhibition of mlgGl response, no inhibition of mIgG2b response; data 
not shown). 
Table 3. 
Inhibition by anti-FcyRII mAb of the mitogenic response to mlgGl or mIgG2b anti-CD3 
mAb from PBMC of two mIgG2b-HR individuals 
Inhibition (%) of Τ cell proliferation 
FC7RII mAb 
IV.3 
KB61 
41H.16 
IV.3 
KB61 
41H.16 
mlgGl 
95 
66 
97 
91 
75 
97 
mIgG2b 
0 
4 
18 
4 
11 
16 
PBMC (1 χ 10s cells) from two mIgG2b-HR individuals were incubated with 10 fig/ml anti-
FC7RII mAb (IV.3, KB61 or 41H. 16) during 30 min. before mlgGl anti-CD3 mAb (WT31, 
100 ng/ml) or mIgG2b anti-CD3 mAb (SPV-ТЗа, 1 Mg/ml) were added. The [3H]-lhymidine 
incorporation was measured during the last 18 hr of the incubation period of 72 hr. 
The percentage inhibition of Τ cell proliferation was calculated. 
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Other cells beside monocytes can function as accessory cells for mIgG2b 
response 
In order to test whether monocytes were the only cell type capable of 
supporting mIgG2b-induced Τ cell proliferation, monocytes were depleted from 
the PBMC of a mIgG2b-HR by a combination of panning with anti-CD 14 mAb 
and phagocytosis of carbonyl-iron. This procedure resulted in a complete 
elimination of the mIgG2a anti-CD3 induced Τ cell response (Table 4). Τ cells 
were still viable as evidenced by the fact that the response to mIgG2a anti-CD3 
could be completely restored (32,396 ± 1,487 c.p.m.) by addition of 
monocytes. The mitogenic response to mIgG2b anti-CD3 mAb was not affected 
by monocyte depletion in the experiment demonstrated in Table 4, although in 
three other experiments the response to mIgG2b was decreased to some extent: 
50-90% of the mIgG2b response observed with PBMC was still present after 
complete removal of monocytes. 
Table 4. 
Anti-CD3 induced Τ cell proliferation of PBMC or monocyte-depleted PBMC from a 
mIgG2b-HR individual. 
Proliferative response (c.p.m.) 
Anti-CD3 mAb PBMC Monocyle-depleted 
subclass 
No mAb 1,253 ± 343 242 ± 34 
mlgGl 13,617 ± 1,813 1,140 ± 222 
mIgG2a 33,109 ± 2,102 290 ± 69 
mIgG2b 8,693 ± 1,153 7,625 ± 1,569 
PBMC or monocyte-depleted PBMC (1 χ 10s cells) from a mIgG2b-HR were incubated with 
anti-CD3/TcR mAb of different subclass; WT32, mIgG2a (50 ng/ml); SPV-ТЗа, mIgG2b (1 
Mg/ml); or WT31, mlgGl (100 ng/ml). In the Τ cell proliferation assay [3H]-thymidine 
incorporation (c.p.m.) was measured during the last 18 hr of the incubation period of 72 hr. 
Monocytes were depleted from PBMC using panning with anti-CD 14 mAb and carbonyl-iron, 
as described in Materials and Methods. The results are given as means ± SD of triplicate 
determinations. 
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Therefore, not only monocytes can support the mitogenic response to mIgG2b 
anti-CD3 mAb but also another cell type that is still present in the monocyte-
depleted cell suspension. 
Accessory cell function of EBV-transformed В cells 
In preliminary experiments we had observed that В cell lines Daudi and Raj i 
could support the mitogenic response to mIgG2b anti-CD3 mAb. In contrast, 
no accessory cell function was measured with the (erythro)-myeloid lines K562, 
U937 and HL-60 (data not shown). Therefore, В cells may be responsible for 
the accessory cell function and support the mIgG2b anti-CD3 induced Τ cell 
proliferation observed after monocytes depletion. We tested the accessory cell 
function of EBV-transformed В cells from mIgG2b-HR and -LR individuals 
(Figure 1). A proliferative response of Τ cells to mIgG2b anti-CD3 mAb was 
found when autologous EBV-B cells from mIgG2b-HR were used as accessory 
cells, but not when EBV-B cells from mIgG2b-LR were used. 
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Figure 1. 
Mitogenic response of Τ cells (1 χ IO5) to anti-CD3 mAb of different subclass (WT32, 
mIgG2a; SPV-ТЗа, mIgG2b; or WT31, mlgGl) in the presence of autologous EBV-B cells 
(2 χ 10*) originating from mIgG2b-HR or mIgG2b-LR individuals. Stimulation indices were 
calculated by dividing c.p.m. obtained in the presence and absence of anti-CD3/TcR mAb. 
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Figure 2. 
Dose-response curve of Τ cell proliferation (1 χ 10s Τ cells) induced by increasing 
concentrations of mIgG2b anti-CD3 mAb (SPV-T3a; 0.1 ng/ml - 10 μg/ml) in the presence 
of autologous EBV-transformed В cells (2 χ IO4 cells) from mIgG2b-HR. [3H]-thymidine 
incorporation was measured during the last 18 hr of the incubation period of 72 hr. Values 
given are means of triplicates. 
Table 5. 
Anti-FcyRII mAb does not inhibit mIgG2b anti-CD3 induced Τ cell proliferation 
supported by autologous EBV-B cells from mIgG2b-HR 
Anti-FC7RII mAb 
IV.3 
KB61 
41H.16 
Inhibition (%) of Τ cell proliferation 
Donor I 
5 
10 
20 
Donor II 
0 
0 
9 
Donor III 
14 
10 
10 
EBV-B cells (2 χ 10* cells) from three different mIgG2b-HR individuals were incubated with 
10 /ig/ml anti-Fc>RII mAb (IV.3, KB61 or 41H.16) during 30 min. before purified 
autologous Τ cells (1 χ 10s cells) and mIgG2b anti-CD3 mAb (SPV-ТЗа, 1 Mg/ml) were 
added. [3H]-thymidine incorporation was measured during the last 18 hr of the incubation 
period of 72 hr. The percentage inhibition of Τ cell proliferation was calculated. 
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Significant proliferation of Τ cells in the presence of mIgG2b-HR EBV-B cells 
was already observed at 1 ng/ml of mIgG2b anti-CD3 (Figure 2). EBV-
transformed В cells (from either mIgG2b-HR or mIgG2b-LR) did not support 
the Τ cell response to mlgGl or mIgG2a anti-CD3 mAb (Figure 1). 
Furthermore, the mitogenic response to mIgG2b anti-CD3 supported by the 
EBV-B cells from mIgG2b-HR was not inhibited by anti-Fc7RII mAb KB61 and 
41H.16 (Table 5). Besides, in immunofluorescence studies, EBV-B cells from 
mIgG2b-HR and mIgG2b-LR showed a positive staining with KB61 and 41H. 16 
but they were negative with the anti-Fc7RII mAb IV.3 and CIKM5. In addition, 
no staining was seen when anti-Fc7RI mAb (32.2 and 197.1) or anti-Fc7RIII 
mAb (Leu 11a and Leu lib) were used (data not shown). 
Table 6. 
EA-mIgG2b resetting by EBV-B cells originating from mIgG2b-HR and mIgG2b-LR 
EBV-HR I 
EBV-HR II 
EBV-HR III 
EBV-HR IV 
EBV-LR 1 
EBV-LR 2 
EBV-LR 3 
Percentage resetting 
At normal ionic strength 
10 ± 3 
16 + 5 
44 ± 4 
40 + 5 
0 
0 
0 
cells 
At low ionic strength 
33 ± 2 
43 ± 5 
77 ± 2 
69 + 1 
0 
0 
0 
EBV-B cells (2 χ 10* cells/ml) from mIgG2b-HR and mIgG2b-LR individuals were incubated 
with 0.5 % (vol/vol) HRBC sensitized with anti-glycophorin A mAb of the mIgG2b isotype. 
The EBV-B cells were incubated at room temperature at normal or at low ionic strength (see 
the Materials and Methods). The percentage of rosettes was scored microscopically. The 
means ± SD of five individual experiments are presented. 
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EA-mIgG2b rosetting of EBV-B cells from mIgG2b-HR individuals 
Our assumption that a polymorphic Fc receptor for mIgG2b is present on 
human EBV-B cells was further supported by rosetting experiments. Human 
RBC coated with mIgG2b anti-glycophorin A mAb (EA-mIgG2b) formed 
rosettes with the EBV-B cells from mIgG2b-HR but not from mIgG2b-LR 
(Table 6). The percentage of rosettes increased when rosetting was performed 
in low ionic strength medium, whereas EBV-B cells from mIgG2b-LR remained 
negative. No rosettes were seen with EA-mlgGl or EA-hlgG, detecting FCYRII 
and Fc7RI, respectively, or with non-sensitized human RBC (data not shown). 
DISCUSSION 
Polymorphism of the mitogenic response to mIgG2b anti-CD3 mAb has been 
observed in several studies. Although no mIgG2b-HR were found in two groups 
of 20 and 12 individuals, respectively (33,41), we have previously reported that 
two individuals out of a group of 30 were mIgG2b-HR (18), and a similar 
frequency (3/27 and 3/30, respectively) was found in two other studies (25,27). 
In the present study we found 18 mIgG2b-HR among 550 individuals (3%). 
With respect to mlgGl, the percentage of high-responders is much higher, 
approximately 70% (16,25,27). Two mIgG2b-HR individuals have been 
reported to be mlgGl-LR (18,25), indicating that high-responsiveness with 
respect to mIgG2b is independent of the mlgGl-responder status. Furthermore, 
we have obtained evidence in recent studies that the mechanism of mIgG2b anti-
CD3 induced Τ cell proliferation is different from mlgGl or mIgG2a induced 
proliferation, since with mIgG2b anti-CD3 no production of IL2 or IFN7 was 
observed, and Τ cell proliferation was not inhibited by anti-IL2R mAb (29). 
We first investigated whether the high-responsiveness to mIgG2b is determined 
by accessory cells, as is the case for mlgGl high-responsiveness. Purified Τ 
cells from mIgG2b-HR individuals could not support the mitogenic response to 
mIgG2b anti-CD3. In the presence of mIgG2b-HR monocytes, however, 
purified Τ cells from a mIgG2b-LR could be induced to proliferate by mIgG2b 
anti-CD3. Therefore, monocytes can function as accessory cells for the mIgG2b 
anti-CD3 induced Τ cell proliferation. 
Depletion of monocytes from PBMC results in a complete elimination of Τ cell 
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proliferation induced by mIgG2a or mlgGl anti-CD3 mAb. By contrast, a 
significant response to mIgG2b was still observed after complete depletion of 
monocytes from mIgG2b-HR PBMC. This indicates that, apart from monocytes, 
other cells present in the mononuclear cell suspension have the capacity to 
support mIgG2b anti-CD3 induced Τ cell proliferation. Because В lymphocytes 
express Fc receptors, and since in preliminary experiments В cell lines Daudi 
and Raji could support the Τ cell response to mIgG2b, we tested the accessory 
function of EBV-transformed В cells derived from mIgG2b-HR or mIgG2b-LR 
individuals. Indeed, EBV-B cells from mIgG2b-HR (but not from mIgG2b-LR) 
could function as accessory cells for the mIgG2b response. To our knowledge, 
human В cells have not been tested before in this model. Mouse В cell blasts 
(obtained after stimulation with lipopolysaccharide, LPS) have been reported to 
be excellent accessory cells which support mIgG2b anti-CD3 induced 
proliferation of human Τ cells, although resting mouse В cells were ineffective 
(28). 
The availability of EBV-transformed cells allowed us to investigate whether the 
accessory function is related to the presence of an Fc receptor for mIgG2b. We 
developed a rosetting technique employing a mIgG2b mAb directed against 
glycophorin A, which is abundantly expressed on human erythrocytes. The 
sensitizing antibody that we used is an isotype switch-variant of the mlgGl 
mAb that we have previously used in our studies on mlgGl polymorphism (17). 
Consistently, we observed rosetting (at a low percentage) with mIgG2b-HR 
EBV-B cells whereas no rosetting was observed with mIgG2b-LR EBV-B cells. 
Jones et al. (40) have reported that the binding of heat-aggregated mIgG2b to 
cell lines U937 and Daudi was strongly enhanced at low ionic strength. We 
therefore tested the effect of ionic strength, and found that the percentage of 
EA-mIgG2b rosettes obtained with EBV-transformed В cells from mIgG2b-HR 
could also be enhanced significantly when medium of low ionic strength was 
used, whereas mIgG2b-LR EBV-B cells remained negative. These findings 
demonstrate that an Fc receptor for mIgG2b is present on human EBV-
transformed В cells, and that at normal ionic strength, this receptor apparently 
has a low-affinity for mIgG2b. 
In immunofluorescence studies, we found no evidence for the presence of 
FC7RI or FCYRIII on EBV-B cells from mIgG2b-HR or mIgG2b-LR. 
Furthermore, mAb IV.3 and CIKM5 (which recognize monocyte Fc-yRII) did 
not bind either. On the other hand, mAb KB61 and 41H.16 (which also bind 
to an isoform of FC7RII that is expressed on В cells (31) did bind to EBV-B 
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cells from both mIgG2b-HR and mIgG2b-LR individuals. However, when mAb 
Г .З, KB61, and 41H.16 were tested for inhibition of anti-CD3 induced Τ cell 
proliferation (using mIgG2b-HR PBMC), the response to mlgGl was strongly 
or even completely inhibited whereas the mIgG2b response was not affected. 
Similar results were obtained when purified monocytes or EBV-B cells from 
mIgG2b-HR individuals were used as accessory cells. Since the epitope 
recognized by Г .З is different from the epitope(s) recognized by KB61 and 
41H. 16 (31), and none of these mAb caused any inhibition of the mIgG2b anti-
CD3 induced Τ cell proliferation, it seems unlikely that FC7RII is involved in 
the mIgG2b polymorphism described here. Nevertheless, the possibility cannot 
be completely ruled out that mIgG2b might bind to a binding site on FC7RII 
that is not affected by binding of any of the anti-Fc-yRII mAb tested in this 
study. 
It is often assumed that FC7RII is the Fc receptor responsible for the binding 
of (polymeric) mIgG2b to human cells. This assumption is partly based on the 
specificity of the murine macrophage FC7RII which binds both mlgGl and 
mIgG2b (42). Furthermore, binding of aggregated mIgG2b to the human 
myeloid cell line U937 is inhibited by anti-Fc7RII mAb IV.3 (40). Since IV.3 
is a mIgG2b mAb, however, this inhibition may be due to the fact that, after 
binding to FC7RII, the Fc moiety of IV.3 binds to an Fc receptor for mIgG2b, 
as pointed out already by the authors (40). Furthermore, cell line U937 may not 
in all aspects be a valid model for human monocytes (and certainly not for 
human В cells). In this respect, it should be stressed that, despite the reported 
binding of aggregated mIgG2b (40), we observed that U937 could not support 
mIgG2b anti-CD3 induced Τ cell proliferation whereas it could support mlgGl 
or mIgG2a anti-CD3 induced proliferation. Another remarkable finding bearing 
on this discussion, comes from studies on monocyte cytotoxicity (ADCC). The 
mIgG2b polymorphism observed in Τ cell proliferation assays was not reflected 
in ADCC: mIgG2b-HR and mIgG2b-LR monocytes were equally effective in 
cytotoxicity against mIgG2b-sensitized erythrocytes (20). These findings could 
be interpreted as evidence for the presence on human monocytes of two binding 
sites for mIgG2b: one binding site (involved in supporting Τ cell proliferation) 
that is polymorphic with respect to binding of mIgG2b, and another one 
(FC7RII?) that is not polymorphic in its binding of mIgG2b. It is noteworthy 
that monocyte cytotoxicity against mIgG2b-sensitized erythrocytes was only 
partially inhibited when both FC7RI and FC7RII had been blocked by mAb (20), 
suggesting that another Fc receptor with affinity for mIgG2b is present on 
human monocytes. 
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In the mouse, multiple isoforms of FC7RII that differ in their functional 
capacities occur on macrophages and В cells (43,44). Multiple FC7RII isoforms 
have also been described in humans (7,8,31). At this moment, it is not clear 
whether the polymorphic binding site for mIgG2b is present on one or more of 
these FC7RII isoforms or on a different Fc receptor. The lack of inhibition by 
anti-Fc7R.II mAb would argue against the first explanation. The functional 
difference that we have observed between anti-CD3 mAb of mlgGl and 
mIgG2b isotype with regard to the dependence of Τ cell proliferation on IL2 
(29) also suggests that the receptor structure binding mIgG2b may be different 
from FC7RII. Further analysis of the mIgG2b polymorphism at the DNA level 
will be necessary to answer these questions. The availability of EBV-
transformed В cell lines expressing this polymorphic receptor will certainly 
facilitate these investigations. 
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The human Fc receptor for mouse IgG2b on monocytes and 
EBV-B cells is functionally inhibited 
by anti-HLA class II antibodies 
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ABSTRACT 
We have recently described a polymorphic Fc receptor for murine IgG2b 
(mIgG2b), present on human monocytes and EBV-transformed В lymphocytes. 
The present study shows that anti-HLA class II monoclonal antibody (mAb) 
completely inhibits both the (Fc receptor-dependent) Τ cell proliferation, 
induced by mIgG2b anti-CD3 mAb, and rosetting with mIgG2b-sensitized 
erythrocytes. This inhibition is also observed with F(ab')2 fragments of anti-
HLA class II mAb, and is therefore not Fc-mediated. The Fc receptor for 
mIgG2b is also present on EBV-transformed В cells obtained from a patient 
with "Bare Lymphocyte Syndrome", that completely lack HLA class II 
antigens. Therefore, the Fc receptor for mIgG2b and HLA class II antigens are 
not identical. Since the low-affinity receptor for IgE (FceRII; CD23) was 
reported to be associated at the cell surface with HLA class II antigens, we 
have compared both types of Fc receptor, and observed that human IgE strongly 
inhibits the mitogenic effect of murine IgE anti-CD3 but not of mIgG2b anti-
CD3 mAb. We conclude that the human Fc receptor for mIgG2b is strongly 
inhibited by anti-HLA class II mAb, but is not identical to HLA class II or 
FceRII. 
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INTRODUCTION 
Receptors for the Fc moiety of IgG (Fc-yR) are involved in a variety of 
immunological processes including phagocytosis, antibody-dependent cell-
mediated cytotoxicity, and the release of several mediators of inflammation. 
Human Fc?R are heterogeneous, and at least three classes of FC7R can be 
distinguished (1,2). Human FC7R can also cross-react with murine (m) IgG. 
The mitogenic response of human Τ cells to murine anti-CD3 monoclonal 
antibody (mAb) requires the interaction of the Fc moiety of the antibody with 
FC7R present on human monocytes. FC7RI can bind mIgG2a, whereas the 
polymorphic FC7RII can, in approximately 70% of normal individuals ("mlgGl 
high-responders", mlgGl-HR) interact with mlgGl (3-6). We have recently 
described a human Fc receptor that is cross-reactive with mIgG2b mAb. This 
receptor is also polymorphic: mononuclear cells from only 3% of normal 
individuals ("mIgG2b high-responders", mIgG2b-HR) exhibit a mitogenic 
response to mIgG2b anti-CD3 mAb (7). The FC7R for mIgG2b could be 
demonstrated on monocytes and on EBV-transformed В cells from mIgG2b-HR, 
but not on cells obtained from mIgG2b low-responders (mIgG2b-LR). This Fc 
receptor appeared to be different from FC7RII since anti-Fc7RII mAb (that 
completely inhibited the mlgGl anti-CD3 mAb induced proliferative response) 
caused no inhibition of the mIgG2b anti-CD3 mAb induced Τ cell proliferation 
(7). Also, the release of IL2 or IFN7, which accompanies mIgG2a or mlgGl 
anti-CD3 mAb induced Τ cell proliferation, was not observed when Τ cell 
proliferation was induced by mIgG2b anti-CD3 mAb (8). 
We now report on the strong inhibitory effect of anti-HLA class II mAb on the 
functioning of the FC7R for mIgG2b. In early studies on murine FC7R, a close 
association between Fc receptors and MHC class II antigens was found. 
Antibodies against MHC class II (but not anti-МНС class I) completely 
inhibited the binding of aggregated immunoglobulins to murine В lymphocytes, 
and this inhibition was not Fc-mediated (9). In studies on human cells, it has 
been reported that anti-HLA class II antibodies strongly inhibit the FC7RI-
dependent proliferation of human mononuclear cells induced by mIgG2a anti-
CD3 mAb (10), but other investigators found no such inhibition (11), or 
inhibition by some but not all anti-HLA-DR antibodies (12). In view of the 
strong inhibition of the FC7R for mIgG2b by anti-HLA class II mAb, we 
investigated whether expression of HLA class II antigen is necessary for the 
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expression of this Fc receptor, and whether HLA class II antigen is perhaps a 
part of (or even identical to) this receptor for mIgG2b. Furthermore, since it 
has been published that the human low-affinity FcR for IgE (FceRII; CD23) is 
spatially associated with HLA-DR antigens (13,14), we have also investigated 
whether the receptor for mIgG2b might be identical to this IgE receptor. 
MATERIALS AND METHODS 
Antibodies: Myeloma protein MOPC 195 (mIgG2b) was purchased from Litton Bionetics 
(Kensington, MD, USA). Hybridoma cell lines producing anti-HLA class I mAb W6/32 
(mIgG2a), or anti-HLA class II mAb L227 (mlgGl), or anti-HLA class II mAb IVA 12 
(mlgGl), were obtained from ATCC (American Type Culture Collection, Rockville, MD, 
USA). The anti-HLA class II mAb anti-HLA-DP (clone B7/21, mlgGl), anti-HLA-DQ 
(clone SK10, mlgGl) and anti-HLA-DR (clone L243, mIgG2a) were obtained from Becton 
Dickinson (Mountain View, CA, USA), whereas mAb OKDR (mIgG2a) was from Ortho 
Diagnostics (Raritan, NJ, USA). These mAb were dialysed extensively before use in order 
to remove the azide. mAb 2-2-1 (mIgG2a), directed against mouse MHC class II (15), as 
well as the anti-HLA class II mAb 12-10 (mIgG2a) and 12-13 (mIgG2b) were developed in 
our laboratory. F(ab')î fragments from mAb 12-10 were obtained by pepsin cleavage, by 
using the Immunopure F(ab')2 preparation kit (Pierce, Rockford, II, USA). The purity of 
these F(ab')2 fragments was tested in a functional assay by measuring their inhibitory effect 
on mIgG2a anti-CD3 induced Τ cell proliferation (see Results). Human IgE (hlgE) serum 
(7800 U/ml) was from Behring (Marburg, Germany). U266, a hlgE producing myeloma cell 
line was obtained from ATCC. Anti-CD3 mAb WT32 (mIgG2a) (3) and anti-TcR mAb 
WT31 (mlgGl) (3,16) were developed in our laboratory. mAb WT31-2b (mIgG2b) is an 
isotype switch-variant obtained from WT31. Anti-CD3 mAb SPV-ТЗа (mIgG2b) (17) was 
a kind gift from Dr. H. Spits (DNAX, Palo Alto, CA, USA), and mlgE anti-CD3 mAb 
CLB-T3/4.E (18) was kindly provided by Dr. R. van Lier, CLB, Amsterdam, The 
Netherlands. Murine IgG2b anti-glycophorin A mAb is an isotype switch-variant of the 
mlgGl mAb that we have previously used to study the polymorphic binding of mlgGl to 
human FC7RII (4), and was a kind gift from Dr. L. Aarden, CLB, Amsterdam, The 
Netherlands. F(ab')2 fragments from anti-glycophorin A were prepared by pepsin cleavage. 
Cells and cell lines: В lymphoblastoid cell line SB was obtained from ATCC. PBMC were 
obtained from buffy coats or from leucocytes isolated by cytapheresis from healthy donors 
by centrifugation on a Ficoll-Hypaque gradient, density 1.077 g/ml (Pharmacia, Uppsala, 
Sweden). Lymphocytes were purified from PBMC by counterflow centrifugation. Monocytes 
were also isolated from PBMC by counterflow centrifugation (19) and were >90% pure, as 
judged by staining with May-Grünwald-Giemsa and non-specific esterase. PBMC and 
monocytes were used directly or cryopreserved and used later. The recovery and viability 
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of the cryopreserved cells was > 70% and > 95 %, respectively. Τ lymphocytes were isolated 
by rosetting with sheep RBC treated with aminoethyl-isothiouronium bromide (20). The 
purified Τ lymphocytes were cryopreserved and used later in the Τ cell proliferation assay. 
EBV-transformed В cells were obtained from mIgG2b high-responders or low-responders, 
as described previously (7). PBMC, monocytes and EBV-transformed В cells were given the 
same identification number as the individual from which they were derived. EBV-transformed 
В cells (Afycop/awna-negative), hybridoma cell lines, and cell line SB were cultured in 
culture medium consisting of RPMI-1640 medium containing Hepes and sodium bicarbonate 
(Gibco BRL, Gaithersburg, MD, USA), supplemented with 10% heat-inactivated FCS 
(Hyclone, Logan, UT, USA), 2 mM glutamine, 1 mM sodium pyruvate, 50 /tg/ml 
streptomycin and 50 IU/ml penicillin. An HLA class Il-negative EBV-transformed В cell line 
obtained from a patient with "Bare Lymphocyte Syndrome" (patient THF, réf. 21)) was 
kindly provided by Dr. P. van den Elsen (Department of Immunohaematology & Bloodbank, 
Leiden, The Netherlands). 
Immunoprecipitation: Cell surface iodination of В lymphoblastoid SB cells was performed 
by the lactoperoxidase method. Cell lysates obtained by solubilization in NP-40 lysis buffer 
were clarified by centrifugation and precleared with Protein A Sepharose 4B CL (Pharmacia 
LKB Biotechnology, Uppsala, Sweden) and with goat anti-mouse IgG (Cappel, Malvern, PA, 
USA) coupled to Sepharose 4B. Aliquots of lysate were treated by three absorption cycles 
with anti-HLA class II mAb OKDR or mAb 12-10, bound to goat anti-mouse IgG on 
Sepharose 4B. Other aliquots of the lysate were left untreated or were absorbed with a non-
relevant mAb (2-2-1), bound to goat anti-mouse IgG-Sepharose. Immunoprecipitation was 
performed on aliquots of untreated or absorbed lysates by incubating with mAb 2-2-1, mAb 
12-10, mAb OKDR, or mAb W6/32 (anti-HLA class I) bound to goat anti-mouse IgG-
Sepharose. The immunoprecipitates were washed before analysis on 10% SDS-PAGE under 
reducing conditions. 
Τ cell proliferation assay'. Τ cell proliferation was measured by a standard fHJ-thymidine 
incorporation assay (3) using either PBMC, or purified autologous Τ cells plus autologous 
accessory cells (monocytes or irradiated (60 Gy) EBV-transformed В cells). Briefly, 105 
PBMC or 105 purified Τ cells plus 2 χ IO4 accessory cells were incubated in the culture 
medium described above in the presence of the following anti-TcR/CD3 mAb: WT31, 100 
ng/ml; WT32, 50 ng/ml; SPV-T3a, 1 ^g/ml; or mlgE anti-CD3, 1 /xg/ml, for 72 hr at 37 
°C in a humidified atmosphere of 5% C0 2 in U-bottom microtitre wells. During the last 18 
hr of the incubation period [3H]-thymidine (1.85 χ IO4 Bq/well) was present. All proliferation 
experiments were performed in triplicate. mAb tested for inhibitory effect were preincubated 
(10 iig/ml, 30 min. at 20 °C) with the cells before the addition of anti-CD3 mAb. The 
percentage inhibition was calculated from the number of c.p.m. obtained in the presence and 
absence of an inhibiting mAb. 
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EA-mlgG2b rosetting assay: Human RBC were sensitized with anti-glycophorin A mAb of 
mIgG2b isotype (EA-mIgG2b), or with F(ab')2 fragments of anti-glycophorin A mAb as a 
negative control. EBV-transformed В cells (2 χ lOVml) were incubated with 0.5% (vol/vol) 
sensitized human RBC for 1 hr at room temperature (20 °C) after centri fugation for 4 min. 
at 20 °C (20 χ g). The percentage of rosettes (& 3 RBC bound) was scored microscopically. 
Rosetting was carried out at normal ionic strength (PBS) or at low ionic strength (a mixture 
of one part of PBS and two parts of a 5% glucose suspension, pH = 7.4) (22). In some 
experiments EBV-transformed В cells were preincubated (30 min. at 4 eC) with anti-HLA 
class II mAb or mIgG2b anti-TcR mAb (WT31-2b), and washed twice before rosetting. 
RESULTS 
Anti-HLA class II mAb inhibits mIgG2b anti-CD3 induced Τ cell 
proliferation 
As described earlier, in mIgG2b-HR individuals no inhibition of the mIgG2b 
anti-CD3 induced mitogenic response was found when PBMC had been 
preincubated with anti-Fc7RII mAb (7). Remarkably, however, a strong 
inhibition of this mitogenic response was observed when the cells had been 
preincubated with mAb 12-10 or 12-13. 
Table 1. 
Anti-HLA class II antibodies inhibit mIgG2b anti-CD3 mAb induced Τ cell proliferation 
mAb 
MOPC 195 
W6/32 
L227 
IVA 12 
12-13 
Subclass 
mIgG2b 
mIgG2a 
mlgGl 
mlgGl 
mIgG2b 
Antigen 
-
HLA class I 
HLA class II 
HLA class II 
HLA class II 
% inhibition" 
31.5 ± 12.0 
18.4 ± 16.6 
99.8 ± 0.5 
99.4 + 0.9 
96.2 ± 5.6 
η 
2 
5 
5 
5 
6 
* PBMC from mIgG2b high-responder individuals were preincubated with 10 /ig/ml of the 
indicated antibodies, and stimulated with 1 /ig/ml of mIgG2b anti-CD3 mAb. Results are 
expressed as the percentage inhibition of [3H]-thymidine uptake after three days of culture. 
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Tissue distribution studies suggested that these antibodies, prepared in our 
laboratory, were directed against HLA-DR. Sequential immunoprecipitation 
studies performed with mAb 12-10 and anti-HLA-DR mAb OKDR clearly 
demonstrated that 12-10 indeed binds to HLA-DR. Similar studies comparing 
mAb 12-10 and 12-13 have shown that 12-13 is also specific for HLA-DR (data 
not shown). Table 1 illustrates the strong inhibitory effect of mAb 12-13, and 
of two other anti-HLA-DR mAb, on the Τ cell proliferation induced by mIgG2b 
anti-CD3 mAb. Three other anti-HLA class II mAb (OKDR, anti-HLA-DR, and 
anti-HLA-DP) also caused essentially complete inhibition of mIgG2b anti-CD3 
mAb induced Τ cell proliferation (90-100% inhibition, four experiments). By 
contrast, mAb anti-HLA class I (W6/32) or mIgG2b myeloma antibody induced 
only marginal inhibition. 
Inhibition by anti-HLA class II mAb is not Fc-mediated 
Since Τ cell proliferation induced by anti-CD3 mAb is Fc-dependent, the 
inhibitory effect of anti-HLA-DR mAb might be Fc-mediated. The fact that 
anti-HLA class II mAb of all subclasses tested (mlgGl, mIgG2a, and mIgG2b) 
all caused complete inhibition of the mIgG2b anti-CD3 induced mitogenic 
response already argues against this explanation. In order to further investigate 
the Fc-dependency of the inhibitory effect, we prepared F(ab')2 fragments of 
anti-HLA-DR mAb 12-10. 
Table 2. 
Inhibition of mIgG2b anti-CD3 mAb induced Τ cell proliferation by anti-HLA class II 
mAb is Fc-independent 
mAb 
12-10 IgG 
12-10 F(ab')2 
Inhibition* of 
mIgG2a response 
1 0 0 + 0 
1.0 ± 9 . 6 
η 
4 
5 
Inhibition" of 
mIgG2b response 
94.4 ± 4.5 
95.6 ± 9.0 
η 
14 
8 
* PBMC from mIgG2b-high-responder individuals were preincubated with 10 /tg/ml of the 
indicated antibody or F(ab')2 fragments, and stimulated with mIgG2a or mIgG2b anti-CD3 
mAb. Results are expressed as the percentage inhibition of [}H]-thymidine uptake after three 
days of culture. 
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Intact (mIgG2a) mAb 12-10 caused complete inhibition of the mitogenic effect 
of both mIgG2a and mIgG2b anti-CD3 mAb. F(ab')2 fragments of mAb 12-10 
did not cause any inhibition of the mIgG2a anti-CD3 mAb induced Τ cell 
proliferation, indicating that these F(ab')2 fragments are completely devoid of 
undigested mIgG2a antibody (Table 2). By contrast, when PBMC from a 
mIgG2b high-responder were preincubated with F(ab')2 fragments of mAb 12-
10 and stimulated with mIgG2b anti-CD3 mAb, a complete inhibition of the Τ 
cell response was still observed (Table 2). Significant inhibition of mIgG2b anti-
CD3 induced Τ cell proliferation already occurred at low concentrations of 
F(ab')2 fragments of mAb 12-10 (73% inhibition at 50 ng/ml, Figure 1). FACS 
analysis showed that approximately half-maximal saturation of HLA-DR was 
obtained at this mAb concentration of 50 ng/ml (data not shown). mAb 12-10, 
12-13, or F(ab')2 fragments of mAb 12-10 caused a similar, strong inhibition 
of mIgG2b anti-CD3 mAb induced Τ cell proliferation when purified monocytes 
or EBV-transformed В lymphocytes from mIgG2b high-responders together with 
autologous Τ cells were used instead of PBMC (Table 3). 
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Figure 1. 
Inhibition of mIgG2b anti-CD3 mAb induced Τ cell proliferation by F(ab')2 fragments of 
anti-HLA class II mAb. PBMC from a mIgG2b high-responder individual were preincubated 
with increasing concentrations of F(ab')2 fragments of mAb 12-10, and stimulated with 
mIgG2b anti-CD3 mAb (1 μg/ml). Results are expressed as percentage inhibition of pH]-
thymidine uptake. 
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Table 3. 
Inhibition by anti-HLA class II mAb of mIgG2b anti-CD3 mAb induced Τ cell 
proliferation in the presence of purified autologous accessory cells 
12-10 
Cell suspension Donor no. 12-10 12-13 F(ab')2 
PBMC 
Monocytes and Τ cells 
1 
5 
1 
2 
3 
1 
2 
3 
97 ± 4* 
90 ± 5 
96+2 
93 ± 2 
92 
88 ± 3 
78+0 
77 ± 10 
100 ± 1 
91 ± 9 
97 + 1 
96 ± 0 
100 
81 ± 8' 
72 + 8" 
74* 
99 
89 ± 14 
98 ± 1 
98 ± 1 
99 
72 ± 3 
71 ± 3 
68 ± 19 
EBV-B cells and Τ cells 
* Results are expressed as percentage inhibition of Τ cell proliferation. Cell suspensions 
(from mIgG2b-HR individuals) were preincubated with 10 /ig/ml of anti-HLA class II mAb 
(or F(ab')2 fragments) and stimulated with 1 μg/ml of mIgG2b anti-CD3 mAb. 
a) Preincubation with 2 Mg/ml 12-13 (instead of 10 μg/mΓ). 
Anti-HLA class II also inhibits EA-mIgG2b rosetting 
EA-rosetting can be used to demonstrate the presence of Fc receptors, and we 
have previously shown that EBV-transformed В cells from mIgG2b-HR can 
form EA-mIgG2b rosettes (7). We observed no such rosettes when F(ab')2 
fragments of the anti-glycophorin A mAb were used to sensitize the 
erythrocytes. This finding confirms the Fc dependency of this EA-rosetting 
technique. EA-mIgG2b rosetting of EBV-transformed В cells from mIgG2b-HR 
(carried out at normal ionic strength) was almost completely blocked by anti-
HLA class II mAb (Figure 2). When EA-mIgG2b rosetting was performed at 
low ionic strength, the percentage of rosetting was higher than at normal ionic 
strength, as reported previously (7), but inhibition by anti-HLA class II was still 
almost complete (data not shown). Both anti-HLA-DP and anti-HLA-DR mAb 
(or F(ab')2 fragments thereof) were inhibitory (Figure 2). No inhibition was 
observed with anti-HLA-DQ mAb, probably as a result of the low expression 
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of HLA-DQ on these EBV-transformed В cells that was measured in 
immunofluorescence studies (data not shown). EA-mIgG2b rosetting was not 
inhibited when EBV-transformed В cells were preincubated with a control mAb 
of mIgG2b subclass (WT31-2b). 
No mAb 
12-10 
12-10 F|ab')2 
12-13 
anti-HLA-DP 
anti-HLA-DQ 
anti-HLA-DR 
Figure 2. 
] 
] 
1 . 1 . , , I , 
10 20 30 4 0 
Percentage EA-mlgG2b rosetting 
5 0 
Inhibition of EA-mIgG2b rosetting of EBV-transformed В cells from a mIgG2b-HR by anti-
HLA class II mAb or F(ab')2 fragments thereof. Cells were preincubated with the indicated 
antibodies, and rosetting was then performed at normal ionic strength. Values given are from 
a representative experiment. Similar inhibition patterns were observed with cells obtained 
from four mIgG2b-HR individuals. Each inhibitory antibody was tested two to four times. 
EA-mIgG2b rosetting of HLA class H-negative EBV-transformed В cells 
One conceivable explanation for the observed inhibition by anti-HLA class II 
mAb (both in the Τ cell proliferation assay and in the EA-mIgG2b rosetting) 
would be provided by identity of the Fc receptor for mIgG2b and HLA class 
II antigens, i.e. direct binding of mIgG2b to HLA class II. We have, however, 
observed EA-mIgG2b rosetting (37 - 49% rosetting observed in five rosetting 
experiments performed at low ionic strength) of EBV-transformed В cells from 
a patient suffering from the "Bare Lymphocyte Syndrome". This patient was 
reported to be completely negative with respect to HLA class II antigen 
expression (21), and we could confirm the absence of HLA class II on the 
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EBV-transformed В cells using immunofluorescence (data not shown). 
Furthermore, the EBV-transformed В cells from this patient were able to 
support the mitogenic response (of heterologous Τ cells) to mIgG2b anti-CD3 
mAb. As expected, EA-mIgG2b rosetting of these EBV-transformed В cells was 
not inhibited by anti-HLA class II mAb (data not shown). These results indicate 
that expression of HLA class II is not required for the binding of mIgG2b 
antibody, and that HLA class II antigen and the Fc receptor for mIgG2b are 
separate structures on the cell membrane of EBV-transformed В cells from 
mIgG2b-HR individuals. 
Fc receptor for mIgG2b appears different from FCÍRII (CD23) 
As mentioned in the Introduction, the human low-affinity receptor for IgE 
(FceRII; CD23) is spatially associated with HLA-DR antigens. We therefore 
tested a possible relationship between this FceRII and the Fc receptor for 
mIgG2b. As shown in Figure 3, the mitogenic response of mononuclear cells 
to mlgE anti-CD3 mAb is strongly inhibited by human serum containing a high 
concentration of IgE (81% inhibition at 78 U/ml). 
6 0 -
50 
ô 
8 40 
* 30 
E d 20 
(J 
10-
mlgE anti-CD3 mAb mlgG2b anti-CD3 mAb 
Figure 3. 
Comparison of the effect of human IgE on Τ cell proliferation induced by mlgE anti-CD3 
or mIgG2b anti-CD3 mAb. PBMC from a mIgG2b-HR individual were stimulated with 100 
ng/ml of anti-CD3 mAb, in the absence (open bars) or presence (shaded bars) of human IgE 
serum (78 U/ml). 
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By contrast, the Τ cell proliferation induced by mIgG2b anti-CD3 mAb was 
hardly affected (14% inhibition) by human IgE. A similar inhibition pattern 
(66% inhibition of mlgE response, 18% inhibition of mIgG2b response at 1000 
U/ml) was obtained when human IgE produced by a myeloma cell line (U266) 
was used instead of serum human IgE. Normal human serum did not inhibit the 
mitogenic effect of mlgE or mIgG2b anti-CD3 mAb (data not shown). 
DISCUSSION 
In a previous publication we have presented evidence for the existence of a 
polymorphic Fc receptor that can interact with mIgG2b. Anti-CD3 mAb of 
mIgG2b subclass was mitogenic for mononuclear cells from mIgG2b-HR 
individuals, and EBV-transformed В cells from such individuals were able to 
form EA-mIgG2b rosettes. The involvement of the Fc moiety of mIgG2b in 
these phenomena was demonstrated by the observation that no rosettes were 
formed when, instead of mIgG2b, a mlgGl mAb of the same specificity was 
used to sensitize the erythrocytes. Furthermore, mIgG2b but not mlgGl anti-
CD3 mAb was mitogenic for purified Τ cells in the presence of EBV-
transformed В cells from mIgG2b-HR (7). The Fc dependency of the EA-
mIgG2b rosetting was confirmed in the present study by the absence of rosettes 
when F(ab')2 fragments of the anti-glycophorin A antibody were used for 
sensitization. 
The purpose of the present study was to investigate the role of HLA class II 
antigens with respect to the human Fc receptor for mouse IgG2b. Several anti-
HLA class II mAb completely inhibited the functioning of this Fc receptor in 
two different assays: mIgG2b anti-CD3 mAb induced Τ cell proliferation, and 
EA-mIgG2b rosetting of EBV-transformed В cells. It has been reported 
previously that anti-HLA class II mAb can inhibit Τ cell proliferation induced 
by mIgG2a anti-CD3 mAb (10,12) although some other anti-HLA class II mAb 
had no effect in this system (11,12). This inhibitory effect was Fc-independent 
since it was also observed with F(ab')2 fragments, and both accessory cells 
(monocytes) and (activated) Τ cells appeared to be targets of the inhibition (10). 
The inhibition that we describe here appears to be different in several respects. 
First, although the anti-HLA class II mAb 12-10 inhibited the mitogenic effect 
of mIgG2a anti-CD3 mAb, F(ab')2 fragments of 12-10 were not inhibitory in 
this assay but they still caused complete inhibition of mIgG2b anti-CD3 mAb 
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induced Τ cell proliferation. The inhibitory effect of F(ab')2 fragments of 12-10 
is therefore specific with respect to the Fc receptor for mIgG2b, since these 
fragments do not affect Τ cell proliferation induced by anti-CD3 mAb of 
mIgG2a subclass, which is dependent on monocyte FC7RI. It is very unlikely 
that in this case the inhibitory effect would be mediated by binding of the anti-
HLA class II mAb to (activated) Τ cells. Furthermore, anti-HLA-DR mAb as 
well as F(ab')2 fragments of 12-10 completely inhibited the formation of EA-
mIgG2b rosettes. These findings strongly suggest that the inhibitory effect 
described here is mediated, at the level of the accessory cell, by a direct 
interference of anti-HLA class II mAb with the functioning of the human Fc 
receptor for mIgG2b. 
How then can antibodies against HLA class II interfere with the binding of 
mIgG2b? One obvious (although not very likely) possibility is that HLA class 
II antigens themselves function as Fc receptor for mIgG2b. The observation that 
a "Bare Lymphocyte Syndrome" patient, completely lacking expression of HLA 
class II, is a high-responder with respect to mIgG2b appears to rule out this 
possibility. Furthermore, we have found no evidence for a particular HLA-DR 
phenotype among the different HLA class li-positive mIgG2b high-responders 
(data not shown). Another possibility is that HLA class II antigens are closely 
associated with the Fc receptor for mIgG2b, as is the case for the low-affinity 
Fc receptor for IgE (13,14). The inhibitory effect of anti-HLA class II mAb on 
both Fc receptors even suggests that these receptors might be identical. Several 
lines of evidence, however, argue against this hypothesis. First, mlgE anti-CD3 
mAb induces Τ cell proliferation with mononuclear cells from all individuals 
(18) whereas mIgG2b anti-CD3 mAb is mitogenic with only 3% of normal 
individuals (7). Furthermore, in this Τ cell proliferation assay mIgG2b anti-CD3 
mAb does not induce IL2 or IFNY (8) whereas mlgE anti-CD3 mAb induced 
Τ cell proliferation is associated with cytokine release (L. Frenken, personal 
communication). The data presented in this study also argue against identity of 
both receptors: human IgE strongly inhibits the mitogenic effect of mlgE anti-
CD3, but not of mIgG2b anti-CD3 mAb. Therefore, the Fc receptor for 
mIgG2b appears to be different from FceRII. It could, however, still be 
associated with HLA class II antigens on the cell surface. In an attempt to 
directly demonstrate such an association, we radiolabeled EBV-transformed В 
cells from a mIgG2b-HR individual, cross-linked the cell lysate, and performed 
immunoprecipitation with anti-HLA-DR mAb. We have been unsuccessful so 
far in immunoprecipitating an additional polypeptide apart from the HLA-DR 
chains, as was described for FctRII (13). This does not exclude the possibility, 
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however, that such an association does exist. Alternatively, it is conceivable 
that the observed inhibitory effect of anti-HLA class II mAb is not due to a 
physical association of HLA class II antigens and the Fc receptor for mIgG2b, 
but is the result of some cellular signalling process mediated by HLA class II 
antigen. It has been reported, for instance, that the binding of anti-HLA-DR can 
induce ILI mRNA and cellular ILI production (23). The precise nature, 
however, of the HLA-DR mediated signal transduction pathway that might play 
a role in the functioning of the Fc receptor for mIgG2b remains to be 
elucidated. Since strong inhibition by anti-HLA class II mAb was also observed 
in the rosetting assay (where the anti-HLA class II antibodies are present for 
only a short time, and at room temperature or below), we favour (despite the 
absence of biochemical proof) the explanation of a cell surface association 
between HLA class II antigens and the Fc receptor for mIgG2b. 
The biological significance of the Fc receptor for mIgG2b on human cells is not 
yet known. Studies to define this receptor at the DNA level are in progress, and 
these studies will hopefully enable us to isolate and transfect the relevant cDNA 
and study the binding characteristics and biological significance of this Fc 
receptor in more detail. 
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Chapter 5 
Proteolysis increases the Fc-mediated binding of murine IgG2b 
to human EBV-transformed В cells, 
but decreases the expression of FCYRII and FceRII 
S. Holtrop, G.P.M. Rijke-Schilder, N.E.M. van Doom, C.W.M. Jacobs, 
R.A.P. Koene and W.J.M. Tax 
Scand. J. Immunol. 38: 259 - 266, 1993. 
ABSTRACT 
We have previously described a polymorphic human Fc receptor for murine 
IgG2b (mIgG2b). This receptor was defined by the binding of (complexed) 
mIgG2b to monocytes and Epstein-Barr virus (EBV)-transformed В cells. Three 
per cent of normal individuals were high-responders with respect to mIgG2b 
(mIgG2b-HR), whereas the other individuals were low-responders for mIgG2b 
(mIgG2b-LR). In the present study we investigated the effect of proteolytic 
enzymes on the Fc-mediated binding of mIgG2b to EBV-B cells. Pronase, 
human leucocyte elastase, and cathepsin G caused an increased binding (in an 
EA-rosetting assay) of mIgG2b to EBV-B cells from mIgG2b-HR, but not from 
mIgG2b-LR. Simultaneous immunofluorescence studies demonstrated that these 
proteolytic enzymes strongly reduced the expression of FCYRII and FceRII on 
these cells, whereas HLA class I or HLA class II molecules were not affected. 
These findings strongly suggest that binding of mIgG2b is not mediated by 
FC7RII or FceRII. We also studied the effect of proteolysis on mIgG2b-HR 
EBV-B cells from an HLA class Il-negative individual. In this case EA-mIgG2b 
rosetting was decreased after proteolysis, suggesting that HLA class II 
molecules may have a role in protecting the binding site for mIgG2b against 
proteolytic destruction. 
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INTRODUCTION 
Specific receptors for the Fc moiety of IgG (FC7R) are expressed on leucocytes, 
and play an important role in the immune defense mechanism. In inflammation, 
Fc7R-positive cells like monocytes and neutrophils are involved in phagocytosis 
(1,2), release of mediators (3), degranulation (4), and antibody dependent cell-
mediated cytotoxicity (ADCC) (5). Three classes of human (h) FCYR have been 
characterized in detail at the cellular and molecular level: FCYRI, FC7RII, and 
FCYRIII. They all belong to the Ig-supergene family and their genes have been 
mapped to chromosome 1 (5,6). Human FCYR can cross-react with murine (m) 
IgG as determined in an anti-CD3 monoclonal antibody (mAb) induced Τ cell 
proliferation assay. The high-affinity receptor, FCYRI (CD64), can bind 
monomeric mIgG2a (7). The polymorphic FC7RII (CD32), a low-affinity 
receptor, can interact with aggregated or complexed mlgGl in 70% of the 
Caucasian individuals (mlgGl high-responders; mlgGl-HR) (8,9). 
Recently, we described a polymorphic human Fc receptor which can interact 
with complexed mIgG2b and which is present on monocytes and (EBV-
transformed) В cells from 3% of healthy Caucasian individuals (10). The 
polymorphism of this receptor was defined using a Τ cell proliferation assay 
(10-12): mIgG2b anti-CD3 mAb was mitogenic for peripheral blood 
mononuclear cells from mIgG2b high-responder individuals (mIgG2b-HR) but 
not from mIgG2b low-responders (mIgG2b-LR). The presence of a human Fc 
receptor for mIgG2b on EBV-transformed В cells from mIgG2b-HR individuals 
was confirmed by EA-rosetting, using mIgG2b-sensitized erythrocytes (10). 
These EBV-transformed В cells do not express FCYRI or FCYRIII, but they do 
express an isoform of Fc7RII. The FcR for mIgG2b, however, appeared to be 
different from FC7RII since the mitogenic response of mIgG2b anti-CD3 mAb 
was not inhibited by anti-Fc7RII mAb (10). Furthermore, Τ cell proliferation 
induced by mIgG2b anti-CD3 mAb was not inhibited by anti-IL2 receptor mAb 
and no release of IL2 or IFN? was measured, whereas Τ cell proliferation 
induced by mIgG2a or mlgGl anti-CD3 mAb (that interacted with FCYRI and 
Fc7RII, respectively) was always accompanied by the release of these cytokines 
and was inhibited significantly by anti-IL2 receptor mAb (13). The FcR for 
mIgG2b seemed to be associated with HLA class II molecules, since anti-HLA 
class II mAb (both intact IgG and F(ab')2 fragments) completely inhibited the 
mIgG2b anti-CD3 mAb induced Τ cell response as well as the EA-mIgG2b 
95 
Chapter 5 
rosetting (14). The FcR for mIgG2b was, however, also expressed on EBV-B 
cells from an HLA class Il-negative individual (14) which indicates that 
expression of HLA class II antigens is not an absolute requirement for binding 
of mIgG2b to human cells. Since the low-affinity receptor for IgE (FceRII; 
CD23) is associated with HLA class II antigens (15), we included this IgE 
receptor in the present study. 
Proteolytic enzymes can have a differential effect on different Fc receptors. The 
Fc receptor for IgE on the human monocytic cell line U937 was reported to be 
trypsin sensitive, whereas the receptor for IgG was trypsin resistant. As a 
matter of fact, the binding of human IgGl was enhanced over that seen with 
untreated cells (16). In studies that were performed many years later, when 
much more was known about the different classes of Fc receptors for IgG, we 
could demonstrate that proteolysis had no effect on human monocyte FcyRI, 
whereas the affinity of human monocyte FC7RII for IgG was strongly increased 
by the proteolytic enzymes trypsin and pronase. The number of FCYRII 
molecules was not affected (17,18). Similar results were obtained with human 
leucocyte elastase (19). An increased EA-rosetting of human monocytes has also 
been observed after treating the monocytes with neuraminidase, an enzyme that 
has no proteolytic activity but that can remove sialic acid from sialo-
glycoproteins (20). 
In the present study EBV-B cells from mIgG2b-HR individuals were treated 
with the serine proteases human leucocyte elastase or cathepsin G, both purified 
from human granulocytes. The percentage of EA-mIgG2b rosettes increased 
after proteolytic treatment, whereas the expression of FCYRII and FceRII was 
strongly reduced. These results support the hypothesis that the FcR for mIgG2b 
is different from FC7RII (CD32) or FceRII (CD23). 
MATERIALS AND METHODS 
Antibodies: Hybridoma cell lines producing anti-HLA class I mAb W6/32 (mIgG2a) or 
HB118 (mlgGl) or anti-HLA class II mAb L227 (mlgGl) or IVA 12 (mlgGl) were obtained 
from ATCC (American Type Culture Collection, Rockville, MD, USA). Anti-HLA class II 
mAb 12-10 (mIgG2a) was developed in our laboratory (14). Anti-CD20 mAb Bl (mIgG2a) 
was from Coulter Immunology (Luton, U.K.). Anti-Fc7RII mAb KB61 (mlgGl) (21), 
41H.16 (mIgG2a) (22) and KuFc79 (mIgG2b) (23) were kindly provided by Drs. D.Y. 
Mason (John Radcliffe Hospital, Oxford, U.K.), Th.F. Zipf (Anderson Hospital and Tumor 
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Institute, Houston, TX, USA) and T. Mohanakumar (Washington University School of 
Medicine, Department of Surgery, St. Louis, MI, USA), respectively. Anti-Fc7RII mAb 
IOM32 (clone 2E1; mIgG2a) (24) and anti-FceRII mAb IOB8 (clone 9P25; mlgGl) were 
obtained from Immunotech SA (Marseille, France). Anti-FceRII mAb Tül (mlgGl) was from 
Biotest AG (Dreieich, Germany). The anti-FceRII mAb 9P25 was kindly provided by Dr. 
J. Banchereau (UNICET, Dardilly, France) (25). Anti-glycophorin A mAb of the mIgG2b 
or mlgGl isotype were a kind gift from Dr. L.A. Aarden (CLB, Amsterdam, The 
Netherlands). MAb anti-transferrin receptor (CD71) was obtained from Becton-Dickinson 
(Mountain View, CA, USA). 
Cells: EBV-transformed В cells were obtained from healthy HLA class Il-positive ( > 95 % 
positive cells) mIgG2b-HR or mIgG2b-LR individuals, as described previously (10). Only 
EBV-B cells that were Mycoplasma-negaúve as tested in a Gen-Probe Mycoplasma Tissue 
Culture II detection system (10) were used. The EBV-B cells were cultured in RPMI-1640 
medium (Dutch modification) containing Hepes and sodium bicarbonate (Gibco BRL, 
Gaithersburg, MD, USA) supplemented with 10% heat-inactivated foetal calf serum (FCS; 
Hyclone, Logan, UT, USA), 2 mM glutamine, 1 mM sodium pyruvate, 50 μg/ml 
streptomycin and 50 IU/ml penicillin in a humidified atmosphere of 5% C0 2 at 37 °C. 
HLA class H-negative EBV-B cells obtained from patients suffering from the "Bare 
Lymphocyte Syndrome", e.g. patient THF (26,27) were kindly provided by Dr. P. van den 
Elsen (Department of Immunohaematology & Bloodbank, Leiden, The Netherlands). 
Reagents: The serine proteases human leucocyte elastase and cathepsin G purified from 
azurophilic granules of human neutrophils were kindly provided by L. Joosten (Department 
of Rheumatology, University Hospital Nijmegen, Nijmegen, The Netherlands). Pronase 
isolated from Streptomyces griseus was obtained from Boehringer Mannheim GmbH 
(Mannheim, Germany). The reagents neuraminidase (type V, isolated from Clostridium 
perfringens); pancreatic elastase (type IV, from porcine pancreas) and PMSF (phenylmethyl-
sulfonyl fluoride, an irreversible inhibitor of serine proteases) were from Sigma Diagnostics 
(St. Louis, MO, USA). 
Treatment of EBV-B cells with proteolytic enzymes or neuraminidase: EBV-B cells (5 χ 10* 
per ml) in serum-free culture medium were treated with increasing concentrations (see 
Results) of proteolytic enzymes and/or protease inhibitor or neuraminidase and incubated for 
30 min. at 37 CC. Ice-cold culture medium containing 10% FCS was added to the cell 
suspension and incubated for 15 min. at 0 °C to inactivate enzymatic activity. Cells were 
washed twice in PBS (phosphate buffered saline; pH = 7.4) alone or PBS containing 1 % 
bovine serum albumine (PBS 1 % BSA) and used for EA-mIgG2b rosetting at normal ionic 
strength or immunofluorescence studies, respectively, as described below. Loss of cells after 
proteolytic treatment with 100 /xg/ml human leucocyte elastase or cathepsin G and washing 
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was 30 ± 9 % (n = 3) and 17 ± 7% (n = 3), respectively. After treatment with 
neuraminidase (100 μg/πй) and washing, 17 ± 3 % (л = 5) of the cells were lost. 
EA-mlgG rosetting assay: EA-mIgG2b or EA-mlgGl rosetting assay at normal ionic strength 
was performed as described (10). Human erythrocytes (HRBC) were maximally sensitized 
with anti-glycophorin A mAb of mIgG2b (EA-mIgG2b) or mlgGl (EA-mlgGl) isotype. 
Briefly, EBV-B cells (2 χ IO6 /ml) were incubated with 0.5% (vol/vol) sensitized HRBC in 
PBS, centrifugated for 4 min. at 20 °C (20 χ g) and incubated for 1 hr at 20 °C (room 
temperature). The percentage of rosettes ( ¿ 3 HRBC bound) was scored microscopically. 
Immunofluorescence assay: Immunofluorescence studies were carried out using standard 
procedures. Briefly, 4 - 5 χ 10s cells were incubated with mAb for 30 min. at 0 °C, washed 
in PBS 1% BSA and 0.1% sodium azide, labeled with FITC-conjugated F (ab'), fragments 
of sheep anti-mouse IgG, heavy and light chain specific (Cappel, Malvem, PA, USA) and 
5000 cells from each sample were analysed in a Coulter Epics flow cytometer. 
RESULTS 
EA-mIgG2b rosetting increases after treatment with proteolytic enzymes 
The effect of the serine proteases leucocyte elastase and cathepsin G on the EA-
mIgG2b rosetting of HLA class Il-positive EBV-B cells from mIgG2b-HR and 
mIgG2b-LR individuals was studied, using varying concentrations (0 - 200 
/ig/ml) of proteolytic enzymes. A two-fold increase of EA-mIgG2b rosetting 
was measured when EBV-B cells from mIgG2b-HR were incubated with a 
concentration of 100 Mg/ml of leucocyte elastase or cathepsin G (Figure 1A). 
Whereas with EBV-B cells from mIgG2b-HR individuals an increased EA-
mIgG2b rosetting was observed after treatment with the serine proteases 
pronase, leucocyte elastase and cathepsin G, no EA-mIgG2b rosetting was 
induced in EBV-B cells from mIgG2b-LR individuals (Table 1). The increase 
of EA-mIgG2b rosetting in EBV-B cells from mIgG2b-HR individuals induced 
by cathepsin G was completely inhibited by PMSF, an irreversible inhibitor of 
serine proteases. PMSF alone had no effect on the percentage of EA-mIgG2b 
rosettes (Table 1). Treatment of EBV-B cells with increasing concentrations of 
pancreatic elastase (up to 200 Mg/ml) had no effect on EA-mIgG2b rosetting 
(data not shown). No induction of EA-mlgGl rosetting was observed in EBV-B 
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cells from mIgG2b-HR or -LR individuals treated with leucocyte elastase, 
cathepsin G or pronase (data not shown). 
Table 1. 
EA-mIgG2b resetting of EBV-B cells from mIgG2b-HR and mIgG2b-LR individuals 
after proteolytic treatment with pronase, leucocyte elastase, cathepsin G and/or PMSF 
Control 
Pronase 
Leucocyte elastase 
Cathepsin G 
Cathepsin G + PMSF 
PMSF 
mIgG2b 
high-responder 
35 ± 2 
56 ± 4 
51 ± 6 
69 ± 6 
31 
33 ± 4 
mIgG2b 
low-responder 
0 
0 
0 
0 
0 
0 
HLA class H-positive EBV-B cells were incubated in the absence or presence of serine 
proteases pronase (250 fig/ml), leucocyte elastase (100 jig/ml) or cathepsin G (100 Mg/ml) 
and/or the serine protease inhibitor PMSF (1 mM) and tested in the EA-mIgG2b resetting 
assay. Results are presented as the percentage of resetting cells, and are mean values from 
one to three experiments. 
Proteolytic treatment strongly reduces FcvRII expression 
In immunofluorescence studies, a strong reduction of FCYRII expression was 
measured when EBV-B cells from mIgG2b-HR individuals were incubated with 
increasing concentrations of leucocyte elastase or cathepsin G (Figure IB). 
Results presented were obtained with anti-Fc7RII m Ab KB61 (Figure IB), but 
similar results were obtained with anti-Fc7RII mAb KuFc79, 2E1, and 41H.16 
(data not shown). Whereas leucocyte elastase, cathepsin G, and pronase 
strongly reduced the expression of FC7RII, they had no effect on the expression 
of HLA class I or HLA class II molecules (Table 2). Similar results as shown 
in Table 2 were obtained with anti-HLA class I mAb HB118, or anti-HLA class 
II mAb L227 and IVA 12. Proteolysis also caused a reduced expression of 
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FC7RII (but not HLA class I or HLA class II) on EBV-B cells from mIgG2b-
LR individuals (data not shown). 
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The percentage of EA-mIgG2b rosettes (A) of HLA class Il-positive EBV-B cells from a 
mIgG2b-HR individual was determined after treatment (30 min. at 37 °C) with increasing 
concentrations (0 - 200 Mg/ml) of leucocyte elastase (shaded bars) or cathepsin G (open bars). 
Simultaneously, FcyRII expression was measured as the percentage of positively stained cells 
with anti-Fc7RII mAb KB61 (B). Results presented are representative for a total of six 
experiments performed with EBV-B cells from three different mIgG2b-HR individuals. 
Proteolysis abolishes expression of FccRII 
The low-affinity FcR for IgE, FceRII/CD23 is expressed on EBV-B cells. Since 
this receptor is spatially associated with HLA class II molecules (15), as also 
seems to be the case with the Fc receptor for mIgG2b, the expression of FctRII 
was also investigated before and after proteolytic treatment. Pronase, leucocyte 
elastase or cathepsin G caused a complete disappearance of the expression of 
FCÍRII as measured by the anti-CD23 mAb IOB8 (Table 2). Similar results 
were measured with anti-FceRII mAb Tiil: a reduction from 97% (before 
proteolysis) to 3% positively stained cells (after proteolysis). The same 
destructive effect of proteolysis on FceRII expression was observed with EBV-B 
cells from mIgG2b-LR individuals (data not shown). No effect was observed 
on the expression of the В cell antigen CD20: more than 99% of anti-CD20 
mAb В1-positively stained cells were measured both before and after proteolytic 
treatment. 
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Table 2. 
Antigen expression on HLA class D-positive EBV-B cells from a mIgG2b-high-responder 
individual before and after proteolysis 
Antigen 
FCYRII 
FceRII 
HLA class I 
HLA class II 
Control 
83 ± 7 
98 ± 2 
99 ± 1 
98 ± 1 
Pronase 
10 ± 5 
2 ± 1 
99 ± 1 
86 ± 8 
Leucocyte 
elastase 
4 ± 1 
1 
99 ± 1 
96 + 2 
Cathepsin G 
5 
3 ± 2 
99 
97 ± 2 
EBV-B cells were incubated in the absence or presence of pronase (250 μg/ml), leucocyte 
elastase (100 μg/ml) or cathepsin G (100 μg/ml). The antigen expression was measured by 
anti-Fc?RII mAb KB61 (« = 1 - 4); anti-FceRII mAb IOB8 (n = 1 - 2); anti-HLA class I 
mAb W6/32 (n = 1 - 4); and anti-HLA class II mAb 12-10 (л = 2 - 3). Results are 
expressed as the percentage (mean ± SD) of positively stained cells in immunofluorescence. 
Proteolytic effects on HLA class Il-negative EBV-B cells 
Recently we have reported that the FcR for mIgG2b and HLA class II antigens 
are separate molecules since HLA class Il-negative EBV-B cells (from a patient 
suffering from the "Bare Lymphocyte Syndrome") are able to form EA-mIgG2b 
rosettes (14). Surprisingly, proteolytic treatment of these EBV-B cells caused 
a reduction of the percentage of EA-mIgG2b rosettes (Figure 2A), in contrast 
to the increased rosetting observed with HLA class Il-positive EBV-B cells. 
Similar to the results obtained with HLA class Il-positive EBV-B cells, the 
expression of FC7RII was strongly reduced after proteolytic treatment (Figure 
2B), and FceRII expression was completely abrogated (the percentage of CD23-
positive cells was reduced from 96% before proteolytic treatment to less than 
3% after proteolysis). HLA class II antigens were absent in these cells, and 
expression of HLA class I antigens was not affected by proteolysis: the 
percentage of HLA class I-positive cells remained more than 97%. 
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Figure 2. 
The percentage of EA-mIgG2b rosettes (A) of HLA class Il-negative EBV-B cells from a 
mIgG2b-HR individual was measured in the absence (open bar) or in the presence of 250 
/tg/ml pronase (hatched bars), 100 Mg/ml leucocyte elastase (black bars) or cathepsin G 
(shaded bar). Simultaneously, Fc>RII expression was determined as the percentage of 
positively stained cells with anti-Fc7RII mAb KB61 (B). The experiment was repeated twice 
with comparable results. * Not determined. 
Neuraminidase affects EA-mIgG2b resetting but not FcR expression 
Reduction of the negative charge of EBV-B cells might result in better adhesion 
of (sensitized) erythrocytes, and an increased percentage of EA-rosettes. 
Therefore, we tested the effect of neuraminidase (an enzyme that removes sialic 
acids from cell surface molecules) on EA-mIgG2b rosetting and FcR expression 
on EBV-B cells. EA-mIgG2b rosetting of (HLA class Il-positive or -negative) 
EBV-B cells from mIgG2b-HR individuals was enhanced after treatment with 
increasing concentrations of neuraminidase (Figure 3). No induction of EA-
mIgG2b rosetting was found with EBV-B cells from mIgG2b-LR individuals 
(data not shown). In contrast to the effects of proteolytic enzymes, no decrease 
of Fc-yRII or FccRII expression was observed when EBV-B cells were treated 
with neuraminidase (FC7RII: 69 + 11% before neuraminidase, 70 ± 9% after 
neuraminidase; FccRII: 98 ± 1% before, 97 ± 2% after neuraminidase; similar 
values were obtained with HLA class Il-negative EBV-B cells). 
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Figure 3. 
EA-mIgG2b rosetting (%) of HL A class li-positive (shaded bars) or HLA class li-negative 
(open bars) EBV-B cells from mIgG2b-HR individuals was measured after treating the cells 
with increasing concentrations of neuraminidase. Results presented are representative of two 
to four experiments. * Not determined. 
DISCUSSION 
Using proteolytic enzymes, we have further characterized the polymorphic 
human Fc receptor that can interact with (polymeric) mIgG2b. Previously, we 
have reported that the induction of Τ cell proliferation by mIgG2b anti-CD3 
mAb requires an accessory function that could be provided by either monocytes 
or (EBV-transformed) В cells from mIgG2b-HR individuals. These EBV-B cells 
do not express FCYRI or Fc7RIII, but they do express an isoform of FCYRII 
(10). Although it is often assumed that human FC7RII is responsible for the 
binding of mIgG2b, there is not much experimental evidence for this 
assumption. In a previous study, we observed that anti-Fc7RII mAb could not 
inhibit the mitogenic response to mIgG2b anti-CD3 mAb. Furthermore, high-
responsiveness for mIgG2b occurs at a frequency (3%) that is different from the 
frequency of (Fc7RII-mediated) mlgGl high-responsiveness (70%), and is 
independent of the responder status with respect to mlgGl (10). Another Fc 
receptor that is expressed on В cells is FctRII (CD23). Since this receptor is 
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associated with HLA class II molecules (IS), and anti-HLA class II mAb 
inhibits the human Fc receptor for mIgG2b (14), it seemed of interest to include 
FccRII as well as Fc-yRII in the present investigation. 
When EBV-B cells from normal (HLA class H-positive) mIgG2b-HR individuals 
were treated with serine proteases (pronase, human leucocyte elastase, or 
cathepsin G), an enhanced EA-mIgG2b rosetting was measured. An increased 
EA-mIgG2b rosetting was also observed when the cells were incubated with 
neuraminidase, indicating that neutralization of negative charge is one 
mechanism causing enhanced EA-rosetting. Since both leucocyte elastase and 
cathepsin G have a high positive charge at neutral pH (pi = 11.0 and pi = 
13.0, respectively), it might be possible that the enhancing effect of these 
enzymes on EA-mIgG2b rosetting was related to neutralization of the negatively 
charged cell membrane of EBV-B cells, rather than to their proteolytic activity. 
Addition of the serine protease inhibitor PMSF (a low molecular weight 
compound that will hardly affect the charge of the enzyme) completely 
abolished the enhancing effect of cathepsin G. Therefore we conclude that the 
proteolytic activity of the serine proteases (and not their positive charge) is 
responsible for the enhancement of EA-mIgG2b rosetting. A remarkable detail 
is that, whereas leucocyte elastase could enhance EA-mIgG2b rosetting, 
pancreatic elastase was unable to do so. A similar observation was made 
previously when the effect of proteolytic enzymes on EA-mlgGl rosetting of 
human myeloid cell lines was studied (19). This may be due to differences in 
the fine specifity of these two elastase enzymes (28). Although leucocyte 
elastase and several other proteases increased the EA-mIgG2b rosetting of 
mIgG2b-HR EBV-B cells, they did not induce EA-mIgG2b rosetting of cells 
obtained from mIgG2b-LR individuals. This is in contrast to the results obtained 
with EA-mlgGl rosetting: when human monocytes from mlgGl-LR individuals 
were treated with proteolytic enzymes, Fc7RII-mediated EA-mlgGl rosetting 
was induced as a consequence of increased affinity of the receptor (17). 
Furthermore, we never observed EA-mlgGl rosetting with EBV-B cells either 
before or after proteolysis. This latter finding may be related to the expression 
of different isoforms of FCÏRII on monocytes and В cells (5,6), but it also 
indicates once again that binding of mIgG2b is independent of the binding of 
mlgGl. 
The expression of FC7RII on EBV-B cells was strongly reduced by proteases, 
again in contrast with monocytes where the number of FC7RII molecules was 
not affected (17). Proteolytic cleavage of FC7RII from the cell membrane was 
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recently reported to occur on activated but not on resting human В cells, 
apparently as a result of endogenous protease activity (29). In view of these 
findings it seemed of interest to determine whether EBV-B cells resemble 
activated or resting В cells, and whether under the experimental conditions there 
is release of soluble Fc receptors (which might inhibit the EA-mIgG2b 
resetting). The EBV-transformed В cells express high levels of HLA-DR and 
CD23 (Table 2). Furthermore, the transferrin receptor was expressed on a 
majority of the cells (81%, 68%, and 58% of the EBV-transformed В cells 
obtained from two mIgG2b-HR and one mIgG2b-LR, respectively). These data 
suggest that the EBV-B cells resemble activated more than resting В cells. In 
contrast, however, to the В cells that were activated by addition of anti-IgM 
antibody (29), no activating stimulus was deliberately given to the EBV-
transformed cells. It is an interesting question whether soluble Fc receptors are 
released from these EBV-B cells by (endogenous) proteases. With respect to 
FC7RII, the high expression of this receptor on the EBV-B cells observed after 
the "control" incubation (no exogenous protease added, Table 2), indicates that 
under the experimental conditions there is apparently no proteolytic cleavage of 
FC7RII by endogenous proteases. With respect to the Fc receptor for mIgG2b, 
the increase of EA-mIgG2b rosetting after the addition of (exogenous) protease 
strongly argues against proteolytic cleavage of the Fc receptor for mIgG2b. 
However, even if soluble Fc receptors were released, they would not interfere 
with the EA-mIgG2b rosetting since several washing steps were performed 
between the incubation of the cells and the EA-rosetting assay. Furthermore, 
the proteolytic treatment of the EBV-transformed cells resulted in an increase, 
not an inhibition of rosetting. In our experiments with exogenous proteases, we 
used the same anti-Fc7RII mAb (KB61) that was used in the study with 
activated В cells (29) to evaluate cell membrane expression of FC7RII. We 
obtained similar results with three other anti-Fc7RII mAb, which excludes the 
possibility that proteolysis might have only damaged one particular epitope of 
the receptor. The strong reduction of FC7RII expression (a small percentage of 
cells remained positive, but even on these cells the number of receptor 
molecules was strongly decreased) at the same time as EA-mIgG2b rosetting 
was increased, indicates that the polymorphic binding of mIgG2b was probably 
not mediated by FC7RII. 
Proteolysis completely abolished the expression of FceRII on EBV-B cells. This 
low-affinity receptor for IgE is easily shed from the cell membrane by 
proteolytic cleavage (30). Although FceRII is associated with HLA class II 
molecules (15), and the Fc receptor for mIgG2b is inhibited by anti-HLA class 
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II mAb (14), we previously reported evidence that these receptors are probably 
not identical since human IgE inhibited the mitogenic response to mlgE anti-
CD3 but not to mIgG2b anti-CD3 mAb (14). The present results (increase of 
EA-mIgG2b rosetting but disappearance of FceRII expression) support the 
conclusion that binding of mIgG2b is not mediated by FceRII. 
The effect of proteolysis was apparently influenced by the presence or absence 
of HLA class II molecules. When EBV-B cells lacking HLA class II molecules 
were treated with proteases, EA-mIgG2b rosetting decreased whereas it 
increased with normal, HLA class Il-positive cells. With both types of EBV-B 
cells, expression of FC7RII and FceRII was strongly reduced by proteolysis. 
The discrepancy between HLA class Il-positive and -negative EBV-B cells with 
respect to the EA-mIgG2b rosetting may indicate that HLA class II molecules 
are involved in stabilizing and protecting the Fc receptor binding site for 
mIgG2b against proteolysis in HLA class Il-positive mIgG2b-HR individuals. 
Earlier studies on a possible relationship between Fc receptors and MHC 
molecules have yielded contradictory results (31,32). It is difficult to compare 
our findings, described here and in a recent publication (14), with the data 
obtained in those early studies because at the time the complex heterogeneity 
of Fc receptors and the existence of cell type-specific isoforms were not yet 
known, and Fc receptors were detected using polyclonal IgG (containing 
different subclasses) and sometimes cell suspensions were used that contained 
several different cell types. 
In vivo, the serine proteases leucocyte elastase and cathepsin G are released 
from granulocytes during activation (e.g. at inflammatory sites). These enzymes 
can have opposite effects on different Fc receptors present on В cells. On the 
one hand, they may induce the release of soluble FC7RII or FceRII from the В 
cells. On the other hand, these proteases may upregulate the Fc receptor that 
is cross-reactive with mIgG2b at sites of inflammation, as was previously 
suggested for monocyte FC7RII (18). Another intriguing possibility is that the 
endogenous proteolytic activity observed in activated В cells (29) could cause 
an upregulation of the Fc receptor for mIgG2b. Since the human ligand of the 
Fc receptor for mIgG2b has not yet been defined, the physiological significance 
of such an upregulation is not yet clear. 
In conclusion, the results of this study provide more evidence that the FcR for 
mIgG2b on (EBV-transformed) В cells is different from FC7RII or FceRII. The 
FcR binding site for mIgG2b seems to be protected and stabilized by HLA class 
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II molecules during proteolysis. Further molecular and functional studies are 
needed to characterize this human FcR for mIgG2b in more detail. 
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Clinical implications of Fe receptor polymorphism 
When monoclonal antibodies (mAbs) became available as an option for 
immunotherapy, it soon became evident that apart from specificity and affinity, 
the isotype of the mAb was important for its effectiveness. Different isotypes 
of murine (m) immunoglobulin exhibited significant differences in their 
capability to interact with human effector systems. Differences in their binding 
to human Fc receptors for IgG (Fc? receptors) were especially prominent. 
Human monocytes could perform antibody-dependent cellular cytotoxicity 
(ADCC) against tumour cells in the presence of murine IgG2a mAb, but only 
slightly or not at all with the mlgGl or mIgG2b subclasses (1). Subsequently, 
it was shown that monomeric mIgG2a (and mIgG3) could bind to human 
monocyte Fc receptors whereas no binding occurred with monomeric mlgGl 
or mIgG2b (2). 
Heterogeneity of human Fey receptors 
In recent years our knowledge of human Fc? receptors, and of their interaction 
with murine immunoglobulins, has rapidly increased. Three main classes of 
human Fc receptors for IgG (Fc?RI, FC7RII, and Fc?RIII) have been defined 
at the molecular level. Several isoforms can be distinguished within each 
receptor class, and further complexity is introduced by various genetic 
polymorphisms (3-5). With respect to murine immunoglobulins, the mIgG2a 
and mlgGl isotypes have been studied in detail, and the specificity and affinity 
of their interaction with human Fc? receptors have been defined. Much less, 
however, was known until recently about the binding of mIgG2b to human Fc 
receptors. We will review here some recent data on the (polymorphic) binding 
of mIgG2b to human cells, and discuss the implications of the polymorphism 
of human Fc? receptors for the immunotherapeutical use of mlgGl or mIgG2b 
mAb. As will be illustrated below, the knowledge obtained from studies on the 
binding of murine immunoglobulins to human Fc receptors can also be very 
useful for the construction of humanized antibodies (containing human Fc 
moieties) for immunotherapy. 
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Interaction of murine IgG2b with human Fc receptors 
In studies employing human cell lines, binding of mIgG2b was only observed 
when the antibody was heat-aggregated, and even then special experimental 
conditions (low ionic strength) were required. In these experiments, the binding 
of polymeric mIgG2b was not mediated by Fc-yRI. There were some indications 
(but no conclusive evidence) for the involvement of FCYRII (6). Indirect 
evidence for Fc-mediated, polymorphic binding of mIgG2b to human cells was 
obtained in Τ cell proliferation assays using mIgG2b anti-CD3 mAb. We had 
previously demonstrated (using mlgGl anti-CD3 mAb) that induction of Τ cell 
proliferation by anti-CD3 mAb requires the interaction of the Fc moiety of the 
antibody with Fc receptors on accessory cells, e.g. monocytes. The mitogenic 
response of peripheral blood mononuclear cells (PBMC) to mlgGl was 
polymorphic: 70% of normal individuals were "mlgGl high-responders", the 
remaining 30% were "mlgGl low-responders" (7,8). We and others reported 
that PBMC from normal individuals also exhibit polymorphism in their 
mitogenic response to mIgG2b anti-CD3 mAb (9-12). Among a group of 550 
individuals, a mitogenic response to mIgG2b anti-CD3 mAb was observed in 
3% ("mIgG2b high-responders") (13). In those individuals, the polymorphic 
receptor for mIgG2b was present on monocytes but also on other mononuclear 
cells that remained after thorough depletion of all monocytes from PBMC 
(13,14). Direct evidence for the presence of an Fc receptor for mIgG2b on 
(Epstein-Barr virus-transformed) human В cells was obtained by EA-rosetting 
(13). 
Although the existence of a polymorphic human Fc receptor for mIgG2b was 
reported by several investigators as discussed above, and is undisputed, the 
molecular identity of this Fc7 receptor has remained elusive so far. This topic 
is confounded by the fact that several different Fc receptors can be present on 
one cell type. Human monocytes, for instance, exhibit mIgG2b-polymorphism 
in the Τ cell proliferation test (13), but monocytes from all donors (irrespective 
of responsiveness to mIgG2b anti-CD3) can perform ADCC against 
erythrocytes that have been highly sensitized with mIgG2b. Apparently, when 
polymeric mIgG2b is present at high concentrations, it can also bind to other 
monocyte Fc receptors that are not polymorphic with respect to mIgG2b (15). 
Although FC7RII may be able to bind polymeric mIgG2b under certain 
conditions (6), several findings argue against the hypothesis that (an isoform of) 
FCYRII is responsible for the polymorphic binding of mIgG2b. First, the 
114 
Clinical implications of Fe receptor polymorphism 
mIgG2b polymorphism is independent of the (Fc7RII-mediated) polymorphism 
with respect to mlgGl : the percentage of mIgG2b high-responders is completely 
different from the percentage of mlgGl high-responders, and the responder-
status with respect to mIgG2b is independent of the responsiveness to mlgGl 
(9). Furthermore, anti-FcyRII antibodies are not inhibitory for mIgG2b anti-
CD3 induced Τ cell proliferation (13). Remarkably, and in contrast to the 
results obtained with mlgGl anti-CD3, the mitogenic effect of mIgG2b anti-
CD3 mAb (in mIgG2b high-responders) is not associated with release of 
interleukin-2 (IL2) or interferon-7 (IFN7), and is not inhibited by anti-IL2 
receptor antibody (16). Additional strong evidence for nonidentity of mIgG2b-
receptor and FC7RII comes from experiments involving proteolytic enzymes. 
Proteolysis increases EA-rosetting mediated by mIgG2b, and at the same time 
decreases the expression of both FC7RII and FceRII (17). Finally, the 
polymorphic receptor for mIgG2b is strongly inhibited by anti-HLA class II 
mAb, in an Fc-independent way. Such an apparent association between Fc 
receptor and HLA-DR is not found with FC7RI or FC7RII (18). Therefore, 
although the polymorphic mIgG2b receptor does not appear to be (an isoform 
of) FC7RII, its identity is still an open question that requires further 
investigations at the molecular level. Another unsolved question is how mIgG2b 
anti-CD3 mAb induces Τ cell proliferation in the absence of IL2. It is also not 
yet known how this Fc receptor for mIgG2b interacts with human IgG of 
different subclasses. In this respect it should be mentioned that the 
polymorphism of FC7RII is also physiologically relevant: mlgGl Iow-responders 
exhibit an effective interaction with human IgG2 complexes whereas mlgGl 
high-responders do not (19). 
Clinical use of mIgG2b or mlgGl antibodies 
So in conclusion, polymeric mIgG2b can bind to a polymorphic Fc receptor in 
a small minority of normal individuals. In addition, it can bind to some extent 
(with a very low-affinity) to mononuclear cells from all individuals through Fc 
receptors that are not polymorphic with respect to mIgG2b. What are the 
implications of these interactions for the immunotherapeutical use of mIgG2b 
mAb? One would expect that in mIgG2b low-responders (the great majority of 
individuals), only target cells that are highly sensitized with mIgG2b would be 
able to interact with the nonpolymorphic binding sites present on monocytes or 
macrophages. Indeed, monocyte ADCC occurred with erythrocytes that were 
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sensitized with very high amounts of mIgG2b (approximately 3 χ IO5 antibody 
molecules per erythrocyte) (15), but not with tumour cells coated with a low 
number of mIgG2b antibody molecules (1). Consistent with this, administration 
of a mIgG2b mAb directed against the CD2 antigen on human Τ cells caused 
only coating in vivo of these Τ cells, and no elimination (and no 
immunosuppressive effect) (20). When the mIgG2b mAb BMA 031, directed 
against the CD3/ Τ cell receptor complex, was administered to renal transplant 
patients, there was only a partial and transient depletion of CD3-positive Τ 
cells. Furthermore, administration of this antibody was not accompanied by 
major side effects (21). This contrasts with the so-called first-dose response 
observed with mIgG2a anti-CD3 mAb OKT3 (and WT32). Fever, chills, and 
several other symptoms usually start within one hour after first administration 
of these mIgG2a antibodies. These symptoms are caused by cytokine release 
associated with (Fc receptor-dependent) Τ cell activation in vivo (22,23). BMA 
031 does not induce IFNY or IL2 in vitro, not even with mononuclear cells 
from mIgG2b high-responders (16), and after administration to renal allograft 
recipients it induces release of tumour necrosis factor but not of ΙΡΝγ or IL2. 
Apparently, synergism between cytokines is required to induce the characteristic 
clinical syndrome (24). Since BMA 031 is specific for the Τ cell receptor (in 
contrast to OKT3 that recognizes the CD3 antigen), it has been argued that the 
different results obtained with this antibody when compared to OKT3 are 
caused by its fine specificity rather than by its isotype. The pathways of Τ cell 
activation by BMA 031 or OKT3 are clearly different (12,25) but the relative 
contributions of isotype and specificity in this respect are not yet clear. Recently 
another mIgG2b mAb (BC3) was administered for treatment of graft-versus-host 
disease. This antibody, directed against a subunit of the CD3 antigen, also 
caused only mild side effects (26). This finding underlines the importance of the 
antibody isotype with respect to the adverse effects associated with anti-CD3/ 
Τ cell receptor antibodies. The exact binding segment in IgG molecules that 
determines the affinity for human Fc receptors has been defined. Using this 
information on the relevant amino acid sequence, the OKT3 antibody molecule 
has been modified in such a way that the FcR binding sequence became similar 
to the one found in mIgG2b. This modified OKT3 is still immunosuppressive 
in vitro, but does not cause Τ cell activation (due to its low-affinity for Fc 
receptors) and may be a good candidate to obtain effective immunosuppression 
without side effects (27). 
What significance has the polymorphism of the Fc receptors for mlgGl and 
mIgG2b in relation to the immunotherapeutical use of these isotypes? It has 
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been reported that elimination of CD8-positive Τ cells after administration of 
mlgGl anti-CD8 m Ab only occurred when the patients were high-responder 
with respect to mlgGl (28). Our own preliminary data concerning WT31, a 
mlgGl mAb directed against the Τ cell receptor, indicate that release of 
cytokines and clinical symptoms of "first-dose response" only occur with 
mlgGl high-responders (Frenken et al., unpublished observations). To our 
knowledge, no mIgG2b high-responder individuals have yet been treated with 
a mIgG2b mAb. Since even with cells from mIgG2b high-responders, mIgG2b 
anti-CD3 mAb did not induce IL2 or IFNY in vitro (as discussed above), we 
would expect that even in mIgG2b high-responder individuals such an antibody 
would not cause cytokine-related side effects. Still it is conceivable that mIgG2b 
high-responder patients respond in a different way to administration of mIgG2b 
mAb than mIgG2b low-responders. It has been reported, for instance, that 
antibody-induced modulation of an antigen from the cell surface can be 
enhanced by interaction of the antibody with an Fc receptor (29). Further 
clinical studies will be needed to define the relevance of Fc receptor 
polymorphism for the effectiveness and safety of mlgGl or mIgG2b antibodies. 
References 
1. Steplewski, Z; Lübeck, MD and Koprowski, H. Human macrophages armed with murine 
immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science 221, 865-867 (1983). 
2. Lübeck, MD; Steplewski, Ζ; Baglia, F; Klein, ΜΗ; Dorrington, KJ and Koprowski, H. The 
interaction of murine IgG subclass proteins with human monocyte Fc receptors. J. Immunol. 135, 
1299-1304 (1985). 
3. Stuart, SG; Simister, NE; Clarkson, SB; Kacinski, BM; Shapiro, M and Mellman, I. Human IgG 
Fc receptor (hFcRII; CD32) exists as multiple isoforms in macrophages, lymphocytes and 
IgG-transporting placental epithelium. EMBOJ. 8, 3657-3666 (1989). 
4. van de Winkel, JGJ and Anderson, CL. Biology of human immunoglobulin G Fc receptors. J. 
Leukoc. Biol. 49, 511-524 (1991). 
5. Tax, WJM and van de Winkel, JGJ. Human Fc gamma receptor II: a standby receptor activated 
by proteolysis? Immunol. Today 11, 308-310(1990). 
6. Jones, DH; Looney, RJ and Anderson, CL. Two distinct classes of IgG Fc receptors on a human 
monocyte line (U937) defined by differences in binding of murine IgG subclasses at low ionic 
strength. J. Immunol. 135, 3348-3353 (1985). 
117 
Chapter 6 
7. Tax, WJM; Willems, HW; Reekers, PPM; Capel, PJA and Koene, RAP. Polymorphism in 
mitogenic effect of IgGl monoclonal antibodies against T3 antigen on human Τ cells. Nature 304, 
445-447 (1983). 
8. Tax, WJM; Hermes, FFM; Willems, RW; Capel, PJA and Koene, RAP. Fe receptors for mouse 
IgGl on human monocytes: polymorphism and role in antibody-induced Τ cell proliferation. J. 
Immunol. 133, 1185-1189(1984). 
9. Tax, WJM; Spits, H; Hermes, HFM; Willems, HM; Capel, PJA and Koene, RAP. Polymorphism 
of human Fc receptors for mouse IgGl and IgG2b. Transplant. Proc. 17, 794-797 (1985). 
10. van Lier, RAW; Boot, JHA; de Groot, ER and Aarden, LA. Induction of Τ cell proliferation with 
anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent 
systems. Eur. J. Immunol. 17, 1599-1604 (1987). 
11. Smith, KG; Austyn, JM; Hariri, G; Beverley, PC and Morris, PJ. Τ cell activation by anti-T3 
antibodies: comparison of IgGl and IgG2b switch variants and direct evidence for accessory function 
of macrophage Fc receptors. Eur. J. Immunol. 16, 478-486 (1986). 
12. Schlitt, HJ; Kurrle, R and Wonigeit, Κ. Τ cell activation by monoclonal antibodies directed to 
different epitopes on the human Τ cell receptor/CD3 complex: evidence for two different modes of 
activation. Eur. J. Immunol. 19, 1649-1655 (1989). 
13. Holtrop, S; Rijke-Schilder, GPM; Koene, RAP and Tax, WJM. A polymorphic Fc receptor for 
mouse IgG2b on human В cells and monocytes. Immunology 74, 613-620 (1991). 
14. Holtrop, S; Rijke-Schilder, GPM; Tamboer, WPM; Koene, RAP and Tax, WJM. Removal of 
monocytes from cell suspensions with anti-CD 14 antibody and carbonyl-iron, using Fc>R-dependent 
accessory function as a sensitive measure of monocyte presence. J. Immunol. Methods 156, 217-222 
(1992). 
15. Boot, JHA; Geerts, ME and Aarden, LA. Functional polymorphisms of Fc receptors in human 
monocyte-mediated cytotoxicity towards erythrocytes induced by murine isotype switch variants. J. 
Immunol. 142, 1217-1223 (1989). 
16. Frenken, LAM; Koene, RAP and Tax, WJM. The role of antibody isotype in IFN-y and IL2 
production during anti-CD3-induced Τ cell proliferation. Transplantation 51, 881-887 (1991). 
17. Holtrop, S; Rijke-Schilder, GPM; van Doorn, NEM; Jacobs, CWM; Koene, RAP and Tax, 
WJM. Proteolysis increases the Fc-mediated binding of murine IgG2b to human EBV-transformed 
В cells, but decreases the expression of Fc-yRII and FccRII. Scand. J Immunol. 38, 259-266 (1993). 
18. Holtrop, S; Rijke-Schilder, GPM; Koene, RAP and Tax, WJM. The human Fc receptor for 
mouse IgG2b on monocytes and EBV-B cells is functionally inhibited by anti-HLA class II antibodies. 
Scand. J Immunol. 37, 195-201 (1993). 
118 
Clinical implications of Fe receptor polymorphism 
19. Warmerdam, РАМ; ал de Winkel, JGJ; Vlug, A; Westerdaal, NAC and Capel, PJA. A single 
amino acid in the second Ig-like domain of the human Fc-γ receptor II is critical for human IgG2 
binding. J. Immunol. 147, 1338-1343 (1991). 
20. Thurlow, PT; Lovering, E; d'Apice, AJF and McKenzie, IFC. A monoclonal anti-pan-T-cell 
antibody. In vitro and in vivo studies. Transplantation 36, 293-298 (1983). 
21. Land, W; Hillebrand, G; Illner, WD; Abendroth, D; Hancke, E; Schleibner, S; Hammer, С and 
Racenberg, J. First clinical experience with a new TcR/CD3-monocIonal antibody (BMA 031) in 
kidney transplant patients. Transpl. Int. 1, 116-117(1988). 
22. Koene, RAP. Immunosuppression by Τ cell antibodies in renal transplantation. Nephron 61, 
383-392 (1992). 
23. Parleviet, KJ and Schellekens, PT. Monoclonal antibodies in renal transplantation: a review. 
Transpl. Int. 5, 234-246 (1992). 
24. Chatenoud, L; Legendre, C; Kurrle, R; Kreis, Η and Bach, JF. Absence of clinical symptoms 
following the first injection of anti-T cell receptor monoclonal antibody (BMA 031) despite isolated 
TNF release. Transplantation 55, 443-445 (1993). 
25. Schwinzer, R; Schutt, HJ and Wonigeit, K. Monoclonal antibodies to common epitopes of the 
human alpha/beta T-celI receptor preferentially activate CD45RA + T-cells. Celllmmunol. 140, 31-41 
(1992). 
26. Anasetti, C; Martin, PJ; Storb, R; Appelbaum, FR; Beatty, PG; Davis, J; Doney, K; Hill, HF; 
Stewart, P; Sullivan, KM and et-al, . Treatment of acute graft-versus-host disease with a 
nonmitogenic anti-CD3 monoclonal antibody. Transplantation 54, 844-851 (1992). 
27. Alegre, ML; Collins, AM; Pulito, VL; Brosius, RA; Olson, WC; Zivin, RA; Knowles, R; 
Thistlethwaite, JR; Jolliffe, LK and Bluestone, JA. Effect of a single amino acid mutation on the 
activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. J 
Immunol. 148, 3461-3468 (1992). 
28. Wee, SL; Colvin, RB; Phelan, JM; Preffer, FI; Reichert, TA; Berd, D and Cosimi, AB. 
Fc-receptor for mouse IgGl (FC7RII) and antibody-mediated cell clearance in patients treated with 
Leu2a antibody. Transplantation Ai, 1012-1017(1989). 
29. Rinnooy Kan, EA; Platzer, E; Weite, К and Wang, CY. Modulation induction of the ТЗ antigen 
by OKT3 antibody is monocyte dependent. J. Immunol. 133, 2979-2985 (1984). 
119 

Chapter 7 
Summary 

Summary 
In the present thesis, the functional polymorphism of the human (h) Fc receptor 
(FcR) that interacts with murine (m) IgG2b antibodies was studied, and its 
relation with the currently known FcR was investigated. An overview of the 
human Fc receptors is given in chapter 1. Of the heterogeneous group of Fc 
receptors, predominantly hFc7RI, hFc7RII and hFceRII are expressed on the 
cells (monocytes and В cells) that are involved in Fc-mediated binding of 
mIgG2b antibodies. Therefore, these Fc receptors are described in some detail, 
and special attention is given to the previously reported polymorphism of 
hFcYRII. The polymorphism of this Fc receptor has been detected in a Τ cell 
proliferation assay. Anti-CD3 m Ab can induce a mitogenic response of Τ cells, 
but this only occurs when the Fc part of the anti-CD3 mAb is able to interact 
with appropriate Fc receptors present on accessory cells. The mitogenic 
response to mIgG2a anti-CD3 mAb is mediated by monocyte I1FC7RI, and 
occurs with peripheral blood mononuclear cells (PBMC) from virtually all 
individuals. On the contrary, a proliferative response of PBMC to mlgGl anti-
CD3 mAb (mediated by monocyte hFc7RII) only occurs in 70% of healthy 
individuals ("high-responders" with respect to mlgGl: mlgGl-HR), but not in 
the remaining 30% of mlgGl "low-responders" (LR). 
Anti-CD3 mAb of mIgG2b isotype is mitogenic for PBMC from less than 10% 
of normal individuals (mIgG2b-HR). In order to determine whether human 
monocytes and/or other cells in the mononuclear cell suspension are responsible 
for the accessory function in Τ cell proliferation induced by mIgG2b anti-CD3 
mAb, a new method for depletion of monocytes was developed (chapter 2). 
This method involved panning with anti-CD 14 mAb, and subsequent removal 
of any remaining monocytes with a magnet after phagocytosis of carbonyl-iron. 
The presence of (hFc7RI-positive) monocytes was measured in a mIgG2a anti-
CD3 mAb induced Τ cell proliferation assay detecting less than 1% of 
monocytes. This method could be used with freshly isolated or cryopreserved 
mononuclear cells. Importantly, mIgG2b anti-CD3 mAb could still induce 
significant Τ cell proliferation after depletion of monocytes suggesting that other 
cells than monocytes (probably В cells) can also function as accessory cells in 
this model. 
The functional polymorphism to mlgGl anti-CD3 mAb (70% mlgGl-HR) 
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located on the hFc7RIIal-encoded molecule expressed in monocytes was found 
to be independent from the mIgG2b-polymorphism. As described in chapter 3, 
high-responsiveness to mIgG2b anti-CD3 mAb was detected in 3% of the 
Caucasian individuals (mIgG2b-HR). Purified monocytes and (EBV-
transformed) В cells derived from mIgG2b-HR were able to support mIgG2b 
anti-CD3 mAb induced mitogenic Τ cell responses. Anti-Fc7RII mAb caused 
no inhibition of the mIgG2b anti-CD3 mAb induced mitogenic response. EBV-B 
cells from mIgG2b-HR could mediate EA-mIgG2b rosetting but no EA-mlgGl 
rosetting was found. These findings indicate that the binding site for mIgG2b 
is different from the binding site for mlgGl, and may even be located on an Fc 
receptor different from I1FC7RII. 
Anti-HLA class II mAb completely inhibited the mIgG2b anti-CD3 mAb 
induced proliferative response as well as EA-mIgG2b rosetting (chapter 4). 
This inhibitory effect was Fc-independent since whole IgG as well as F(ab')2 
fragments thereof abolished the response. The FcR for mIgG2b was also present 
on HLA class Il-negative EBV-B cells (from patients suffering from the "Bare 
Lymphocyte Syndrome"), which indicates that the FcR for mIgG2b is not 
identical to HLA class II, and does not require HLA class II molecules for its 
expression. In previous studies an association of HLA class II molecules with 
hFccRII/CD23 on В cells had been reported. However, the involvement of 
hFceRII in the binding of mIgG2b antibodies seemed to be unlikely because 
human IgE inhibited the mlgE anti-CD3 mAb induced Τ cell proliferation 
whereas no inhibition of the mIgG2b anti-CD3 mAb induced response was 
observed. 
Additional evidence that the FcR for mIgG2b on В cells was different from 
hFcyRII or hFceRII was obtained in studies on proteolysis (chapter 5). EBV-B 
cells from mIgG2b-HR individuals with normal HLA class II expression treated 
with exogenously added serine proteases (e.g. human leucocyte elastase or 
cathepsin G), showed an increase in EA-mIgG2b rosetting whereas the 
expression of both hFcyRII and hFceRII was strongly reduced. Remarkably, 
proteolysis caused a reduced EA-mIgG2b rosetting in EBV-B cells from HLA 
class Il-negative individuals. These data suggest that the Fc-binding epitope for 
mIgG2b in mIgG2b-HR individuals may be protected by HLA class II 
molecules against proteolytic damage. 
The clinical significance of the polymorphic interaction of mIgG2b antibodies 
with human Fc receptors is discussed in chapter 6. When anti-CD3 antibody 
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is administered for immunosuppression in transplant recipients, the Fc moiety 
of the monoclonal antibody may interact with appropriate Fc receptors and 
initiate release of cytokines which are responsible for the side effects in vivo. 
Such a first-dose effect is seen with mIgG2a anti-CD3 mAb in all individuals. 
Preliminary data indicate that for mlgGl anti-CD3 mAb this effect only occurs 
in mlgGl-HR individuals. With respect to mIgG2b, the majority of individuals 
demonstrates low-affinity for mIgG2b antibodies. In vitro studies revealed that 
mIgG2b anti-CD3 mAb caused no release of cytokines, not even with mIgG2b-
HR cells. Therefore, in vivo use of mIgG2b anti-CD3 antibodies might be 
promising in future studies on immunosuppression. Indeed, the administration 
of BMA 031, a mIgG2b (anti-T cell receptor) mAb was not associated with 
severe side effects. 
The investigations summarized above do not provide a definitive answer to the 
question which human Fc receptor is responsible for the polymorphic binding 
of mIgG2b antibodies. However, they strongly suggest that the Fc receptor for 
mIgG2b is different from hFc7RI, I1FC7RII, hFc7RIII or hFceRII, for the 
following reasons: 
- EBV-transformed В cells from mIgG2b-HR individuals can mediate EA-
mIgG2b rosetting, and can support the mitogenic effect of mIgG2b anti-CD3 
mAb, but they do not express hFc-yRI or hFc7RIII (chapter 3). 
- The hFc7RII is expressed on monocytes and В cells, and several isoforms of 
this receptor have been described. It is very unlikely, however, that hFc7RII 
is responsible for the polymorphic interaction with mIgG2b. Anti-Fc7RII mAb 
do not inhibit mIgG2b anti-CD3 mAb induced Τ cell proliferation (chapter 3). 
A second, and probably even more convincing, argument is that proteolytic 
enzymes increase EA-mIgG2b rosetting and at the same time drastically 
decrease the expression of hFc7RII (chapter 5). 
- The same argument holds with respect to hFceRII (chapter 5). Furthermore, 
the mitogenic response to mIgG2b anti-CD3 mAb is not inhibited by human IgE 
(chapter 4). 
In future studies a characterization of the molecular structure of the Fc receptor 
that interacts with murine IgG2b may provide the molecular basis of the 
functional polymorphism described in the present study. 
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Samenvatting 
In dit proefschrift is een funktioneel polymorfisme beschreven van een humane 
(h) Fe receptor (FcR), die een interaktie kan aangaan met IgG2b antistoffen 
afkomstig van de muis (mIgG2b). De relatie van deze receptor met de tot nu 
toe bekende Fe receptoren is onderzocht. Een overzicht van de humane Fe 
receptoren is gegeven in hoofdstuk 1. Van een heterogene groep van Fe 
receptoren worden voornamelijk hFc7RI, IIFCYRII en hFceRII geëxprimeerd op 
de cellen (monocyten en В lymfocyten) die betrokken zijn bij de Fc-
gemediëerde binding van muize IgG2b antistoffen. Deze Fe receptoren zijn dan 
ook uitgebreider beschreven waarbij speciale aandacht is geschonken aan het al 
eerder gevonden polymorfisme met betrekking tot de humane Fc7RII. Het 
polymorfisme van deze Fe receptor werd voor het eerst beschreven in een Τ cel 
proliferatie-test. Anti-CD3 monoclonale antistoffen zijn in staat een mitogene 
Τ cel respons te induceren, maar dit vindt alleen plaats wanneer het Fc-gedeelte 
van de anti-CD3 antistof een interactie kan aangaan met geschikte Fc-receptoren 
op ondersteunende cellen. De mitogene respons op mIgG2a anti-CD3 antistoffen 
wordt gemediëerd door hFcvRI, en is gevonden met perifere bloed 
mononucléaire cellen (PBMC) van vrijwel alle individuen. Daarentegen vindt 
een proliferatieve respons van PBMC in aanwezigheid van mlgGl anti-CD3 
antistoffen (gemediëerd door IIFCYRII op monocyten) plaats bij 70% van de 
gezonde individuen ('high-responders' met betrekking tot mlgGl: mlgGl-HR), 
maar niet bij de resterende 30% mlgGl 'low-responders' (LR). 
De anti-CD3 antistof van het mIgG2b isotype is mitogeen in PBMC van minder 
dan 10% van de normale individuen (mIgG2b-HR). Om te bepalen of humane 
monocyten en/of andere cellen in de mononucléaire celsuspensie 
verantwoordelijk zijn voor de ondersteunende funktie in de Τ cel proliferatie 
geïnduceerd door mIgG2b anti-CD3 antistoffen, is een nieuwe methode 
ontwikkeld om monocyten te elimineren (hoofdstuk 2). Deze methode omvat 
eerst 'panning' met anti-CD14 antistoffen waarbij vervolgens de nog resterende 
monocyten, na opname van carbonyl-ijzer werden verwijderd met een magneet. 
De aanwezigheid van (hFcYRI-positieve) monocyten werd gemeten in een 
mIgG2a anti-CD3 antistof geïnduceerde Τ cel proliferatie-test waarbij de 
aanwezigheid van minder dan 1% monocyten nog gedetecteerd kon worden. 
Deze methode is bruikbaar voor zowel vers geïsoleerde als in vloeibare stikstof 
bewaarde mononucléaire cellen. Belangrijk is, dat na het verwijderen van de 
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monocyten de mIgG2b anti-CD3 antistof geïnduceerde Τ cel proliferatie nog 
steeds gemeten kon worden. Dit veronderstelt dat andere cellen dan monocyten 
(waarschijnlijk В lymfocyten) in staat zijn om als ondersteunende cel in dit 
model te fungeren. 
Het funktionele polymorfisme voor mlgGl anti-CD3 antistoffen (70% mlgGl -
HR individuen) op monocyten gecodeerd door hFc7RIIal, is onafhankelijk van 
het mIgG2b-polymorfisme. Zoals beschreven in hoofdstuk 3, is een sterke 
respons op mIgG2b anti-CD3 antistoffen waargenomen bij slechts 3% van de 
individuen (mIgG2b-HR). Gezuiverde monocyten en (met EBV-
getransformeerde) В lymfocyten afkomstig van mIgG2b-HR, zijn in staat om 
de mIgG2b anti-CD3 antistof geïnduceerde mitogene Τ cel respons te 
ondersteunen. Anti-Fc7RII antistoffen veroorzaken geen remming van deze 
mitogene respons. EBV-B lymfocyten van mIgG2b-HR kunnen wel de EA-
mIgG2b rozettering mediëren maar er werd geen EA-mlgGl rozettering 
gevonden. Deze gegevens wijzen erop, dat de bindingsplaats voor mIgG2b 
verschillend is van de bindingsplaats voor mlgGl, of zelfs gelokaliseerd kan 
zijn op een Fe receptor die een andere is dan hFcyRII. 
Antistoffen gericht tegen HLA klasse II antigenen geven volledige remming van 
zowel de mIgG2b anti-CD3 antistof geïnduceerde Τ cel proliferatie alsmede de 
EA-mIgG2b rozettering (hoofdstuk 4). Dit remmende effect is onafhankelijk 
van het Fc-gedeelte van het IgG omdat zowel het complete IgG als de F(ab')2 
fragmenten ervan de respons volledig remmen. De Fe receptor voor mIgG2b 
is ook gevonden op HLA klasse Il-negatieve EBV-B lymfocyten (van patiënten 
die lijden aan het 'Bare Lymphocyte Syndrome'). Dit betekent dat de Fe 
receptor voor mIgG2b niet identiek is aan HLA klasse II, en dat HLA klasse 
II molekulen ook niet nodig zijn voor de expressie deze Fe receptor. In 
voorgaande studies is een associatie op В lymfocyten beschreven van HLA 
klasse II molekulen met hFc€RII/CD23. Echter, de betrokkenheid van hFccRII 
bij de binding van mIgG2b antistoffen lijkt niet aannemelijk omdat humaan IgE 
wel de mlgE anti-CD3 antistof geïnduceerde Τ cel proliferatie remt, maar geen 
inhibitie geeft van de mIgG2b anti-CD3 antistof geïnduceerde respons. 
Aanvullende bewijzen dat de Fe receptor voor mIgG2b op В lymfocyten 
verschillend is van hFc7RII of hFceRII, zijn verkregen in studies naar effecten 
van Proteolyse (hoofdstuk 5). EBV-B lymfocyten van mIgG2b-HR individuen 
met een normale HLA klasse II expressie en behandeld met exogeen 
toegevoegde serine proteases (b.v. humaan leucocyt elastase en cathepsine G), 
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vertonen een verhoogde EA-mIgG2b rozettering terwijl de expressie van zowel 
I1FC7RII als hFccRII sterk gereduceerd is. Opmerkelijk is, dat met EBV-B 
lymfocyten van HLA klasse H-negatieve individuen na Proteolyse, een 
verlaagde EA-mIgG2b rozettering gevonden werd. Deze gegevens suggereren 
dat het Fc-bindende epitoop voor mIgG2b in mIgG2b-HR individuen door HLA 
klasse II moleculen beschermd wordt tegen proteolytische schade. 
De klinische betekenis van de polymorfe interaktie van mIgG2b antistoffen met 
humane Fe receptoren wordt besproken in hoofdstuk 6. Wanneer ter bestrijding 
of voorkoming van afstoting anti-CD3 antistoffen toegediend worden aan een 
ontvanger van een transplantaat, is het mogelijk dat het Fc-gedeelte van de 
monoclonale antistof een interaktie kan aangaan met een geschikte Fe receptor 
waarbij cytokines kunnen vrijkomen, die verantwoordelijk zijn voor de 
bijwerkingen die in vivo worden gevonden. Dit "eerste dosis-effect" wordt na 
toediening van mIgG2a anti-CD3 antistoffen gevonden bij alle individuen. 
Voorlopige gegevens met mlgGl anti-CD3 antistoffen duiden erop, dat dit 
effect alleen voorkomt bij mlgGl-HR individuen. Met betrekking tot mIgG2b 
is gebleken, dat het merendeel van de individuen een lage affiniteit voor 
mIgG2b antistoffen heeft. In vitro studies hebben uitgewezen dat bij gebruik van 
mIgG2b anti-CD3 antistoffen geen cytokines vrijkomen, ook niet door cellen 
van mIgG2b-HR. Gebruik, in vivo, van mIgG2b anti-CD3 antistoffen zou 
daarom veelbelovend kunnen zijn in toekomstige studies op het gebied van de 
immuunsuppressie. Inderdaad ging de toediening van BMA 031, een mIgG2b 
(anti-T cel receptor) antistof niet gepaard met sterke bijwerkingen. 
Het onderzoek zoals hierboven samengevat, geeft geen definitief antwoord op 
de vraag welke humane Fe receptor verantwoordelijk is voor de polymorfe 
binding van mIgG2b antistoffen. De Fe receptor voor mIgG2b lijkt in ieder 
geval verschillend te zijn van hFc7RI, hFc7RII, hFc7RIII of hFccRII, om de 
volgende redenen: 
- EBV-getransformeerde В lymfocyten van mIgG2b-HR individuen kunnen de 
EA-mIgG2b rozettering mediëren en kunnen het mitogene effect van mIgG2b 
anti-CD3 antistoffen ondersteunen, maar zij exprimeren hFc7RI of hFc7RIII 
niet (hoofdstuk 3). 
- hFc7RII wordt tot expressie gebracht op monocyten en В lymfocyten. 
Verschillende isovormen van deze receptor zijn beschreven. Het is echter niet 
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waarschijnlijk dat hFc7RII verantwoordelijk is voor de polymorfe interaktie met 
mIgG2b. Anti-FcyRII antistoffen remmen immers de mIgG2b anti-CD3 antistof 
geïnduceerde Τ cel proliferatie niet (hoofdstuk 3). Een tweede, en waarschijnlijk 
meer overtuigend argument is dat behandeling met proteolytische enzymen de 
EA-mIgG2b rozettering verhoogt maar tegelijkertijd een drastische verlaging 
van de expressie van hFc7R.II teweegbrengt (hoofdstuk 5). 
- Hetzelfde argument geldt ook met betrekking tot hFceRII (hoofdstuk 5). 
Bovendien wordt de mitogene respons van mIgG2b anti-CD3 antistoffen niet 
geremd in aanwezigheid van humaan IgE (hoofdstuk 4). 
In toekomstige studies zal een karakterisering van de moleculaire struktuur van 
de humane Fe receptor die een interaktie aangaat met mIgG2b, mogelijk 
opheldering verschaffen over de moleculaire achtergronden van het funktionele 
polymorfisme zoals beschreven in deze studie. 
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